

**ALPHA AMINO ACID DERIVATIVES-- INHIBITORS OF
LEUKOCYTE ADHESION MEDIATED BY VLA-4**

5

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Patent Application Serial
No. 60/220,132, filed July 21, 2000, the disclosures of which are incorporated
herein by reference in their entirety.

10

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to certain alpha amino acid derivatives which
inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by
VLA-4.

15

References

The following publications, patents and patent applications are cited
in this application as superscript numbers:

20

- ¹ Hemler and Takada, *European Patent Application Publication*
No. 330,506, published August 30, 1989
- ² Elices, et al., *Cell*, 60:577-584 (1990)
- ³ Springer, *Nature*, 346:425-434 (1990)
- ⁴ Osborn, *Cell*, 62:3-6 (1990)
- ⁵ Vedder, et al., *Surgery*, 106:509 (1989)
- ⁶ Pretolani, et al., *J. Exp. Med.*, 180:795 (1994)
- ⁷ Abraham, et al., *J. Clin. Invest.*, 93:776 (1994)
- ⁸ Mulligan, et al., *J. Immunology*, 150:2407 (1993)
- ⁹ Cybulsky, et al., *Science*, 251:788 (1991)

25

30

35

40

002010-680

- 5 10 Li, et al., *Arterioscler. Thromb.*, 13:197 (1993)
- 11 Sasseville, et al., *Am. J. Path.*, 144:27 (1994)
- 12 Yang, et al., *Proc. Nat. Acad. Science (USA)*, 90:10494
10 (1993)
- 13 Burkly, et al., *Diabetes*, 43:529 (1994)
- 14 Baron, et al., *J. Clin. Invest.*, 93:1700 (1994)
- 15 15 Hamann, et al., *J. Immunology*, 152:3238 (1994)
- 16 Yednock, et al., *Nature*, 356:63 (1992)
- 17 Baron, et al., *J. Exp. Med.*, 177:57 (1993)
- 20 18 van Dinther-Janssen, et al., *J. Immunology*, 147:4207 (1991)
- 19 van Dinther-Janssen, et al., *Annals. Rheumatic Dis.*, 52:672
25 (1993)
- 20 Elices, et al., *J. Clin. Invest.*, 93:405 (1994)
- 21 Postigo, et al., *J. Clin. Invest.*, 89:1445 (1991)
- 30 22 Paul, et al., *Transpl. Proceed.*, 25:813 (1993)
- 23 Okarhara, et al., *Can. Res.*, 54:3233 (1994)
- 24 Paavonen, et al., *Int. J. Can.*, 58:298 (1994)
- 35 25 Schadendorf, et al., *J. Path.*, 170:429 (1993)
- 26 Bao, et al., *Diff.*, 52:239 (1993)
- 40 27 Lauri, et al., *British J. Cancer*, 68:862 (1993)
- 28 Kawaguchi, et al., *Japanese J. Cancer Res.*, 83:1304 (1992)
- 29 Kogan, et al., *U.S. Patent No. 5,510,332*, issued April 23,
45 1996
- 30 International Patent Appl. Publication No. WO 96/01644

00022020207660

5 All of the above publications, patents and patent applications are
herein incorporated by reference in their entirety to the same extent as if
each individual publication, patent or patent application was specifically and
individually indicated to be incorporated by reference in its entirety.

10 State of the Art

VLA-4 (also referred to as $\alpha_4\beta_1$ integrin and CD49d/CD29), first
identified by Hemler and Takada¹ is a member of the β_1 integrin family of
cell surface receptors, each of which comprises two subunits, an α chain and
a β chain. VLA-4 contains an α_4 chain and a β_1 chain. There are at least
15 nine β_1 integrins, all sharing the same β_1 chain and each having a distinct α
chain. These nine receptors all bind a different complement of the various
cell matrix molecules, such as fibronectin, laminin, and collagen. VLA-4,
for example, binds to fibronectin. VLA-4 also binds non-matrix molecules
that are expressed by endothelial and other cells. These non-matrix
20 molecules include VCAM-1, which is expressed on cytokine-activated
human umbilical vein endothelial cells in culture. Distinct epitopes of VLA-
4 are responsible for the fibronectin and VCAM-1 binding activities and each
activity has been shown to be inhibited independently.²

25 Intercellular adhesion mediated by VLA-4 and other cell surface
receptors is associated with a number of inflammatory responses. At the site
of an injury or other inflammatory stimulus, activated vascular endothelial
cells express molecules that are adhesive for leukocytes. The mechanics of
leukocyte adhesion to endothelial cells involves, in part, the recognition and
30 binding of cell surface receptors on leukocytes to the corresponding cell
surface molecules on endothelial cells. Once bound, the leukocytes migrate
across the blood vessel wall to enter the injured site and release chemical
mediators to combat infection. For reviews of adhesion receptors of the
immune system, *see*, for example, Springer³ and Osborn⁴.

5 Inflammatory brain disorders, such as experimental autoimmune
encephalomyelitis (EAE), multiple sclerosis (MS) and meningitis, are
examples of central nervous system disorders in which the
endothelium/leukocyte adhesion mechanism results in destruction to
otherwise healthy brain tissue. Large numbers of leukocytes migrate across
10 the blood brain barrier (BBB) in subjects with these inflammatory diseases.
The leukocytes release toxic mediators that cause extensive tissue damage
resulting in impaired nerve conduction and paralysis.

15 In other organ systems, tissue damage also occurs via an adhesion
mechanism resulting in migration or activation of leukocytes. For example,
it has been shown that the initial insult following myocardial ischemia to
heart tissue can be further complicated by leukocyte entry to the injured
tissue causing still further insult (Vedder et al.⁵). Other inflammatory or
20 medical conditions mediated by an adhesion mechanism include, by way of
example, asthma⁶⁻⁸, Alzheimer's disease, atherosclerosis⁹⁻¹⁰, AIDS
dementia¹¹, diabetes¹²⁻¹⁴ (including acute juvenile onset diabetes),
inflammatory bowel disease¹⁵ (including ulcerative colitis and Crohn's
disease), multiple sclerosis¹⁶⁻¹⁷, rheumatoid arthritis¹⁸⁻²¹, tissue
25 transplantation²², tumor metastasis²³⁻²⁸, meningitis, encephalitis, stroke, and
other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis,
myocardial ischemia and acute leukocyte-mediated lung injury such as that
which occurs in adult respiratory distress syndrome.

30 In view of the above, assays for determining the VLA-4 level in a
biological sample containing VLA-4 would be useful, for example, to
diagnosis VLA-4 mediated conditions. Additionally, despite these advances
in the understanding of leukocyte adhesion, the art has only recently
addressed the use of inhibitors of adhesion in the treatment of inflammatory


09910702-072001

5 brain diseases and other inflammatory conditions^{29,30}. The present invention addresses these and other needs.

SUMMARY OF THE INVENTION

10 This invention provides compounds which bind to VLA-4. Such compounds can be used, for example, to assay for the presence of VLA-4 in a sample and in pharmaceutical compositions to inhibit cellular adhesion mediated by VLA-4, for example, binding of VCAM-1 to VLA-4. The compounds of this invention have a binding affinity to VLA-4 as expressed by an IC₅₀ of about 15 μM or less (as measured using the procedures described in Example A below).

15 Accordingly, in one of its composition aspects, this invention is directed to a compound of Formula (Ia) or (Ib):



wherein:

30 Ar¹ is an aryl, heteroaryl, cycloalkyl, or heterocyclic group wherein said aryl, heteroaryl, cycloalkyl, or heterocyclic group is optionally substituted, on any ring atom capable of substitution, with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino,

5 substituted amino, amidino, alkyl amidino, thioamidino, aminoacyl,
aminocarbonylamino, aminothiocabonylamino, aminocarbonyloxy, aryl,
substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted
aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, carboxyl, cycloalkyl,
substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl,
10 substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl,
substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl,
thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted
heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted
cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy,
15 substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino,
-OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted
aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-
heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-NRR where each R is
independently hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted
20 alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl,
-NRS(O)₂-substituted heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-
substituted heterocyclic, -NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted
alkyl, -NRS(O)₂-NR-aryl, -NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-
heteroaryl, -NRS(O)₂-NR-substituted heteroaryl, -NRS(O)₂-NR-heterocyclic,
25 -NRS(O)₂-NR-substituted heterocyclic where R is hydrogen or alkyl,
-N[S(O)₂-R']₂ and -N[S(O)₂-NR']₂ where each R' is independently selected
from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

R¹ is selected from the group consisting of hydrogen, alkyl,
30 substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted
cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

Ar² is an aryl or heteroaryl group optionally substituted, in addition
to ring B or C, with one or two substituent(s) selected from the group

09910702-072001

consisting of hydrogen, halogen, hydroxy, alkoxy, substituted alkoxy, acyloxy, amino, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, acylamino, aminoacyl, N-acyl-N-alkylamino, substituted N-acyl-N-alkylamino, (alkylsulfonyl)amino, substituted (alkylsulfonyl)amino, N-(alkylsulfonyl)-N-alkylamino, substituted N-(alkylsulfonyl)-N-alkylamino, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, cyano, acyl, substituted acyl, carboxy, substituted carboxy, thiol, alkylthio, substituted alkylthio, alkylsulfoxy, substituted alkylsulfoxy, alkylsulfonyl, and substituted alkylsulfonyl;

Z is -O- or -S-;

B is a group wherein W, together with $-C(=Z)NR^2-$, forms a saturated or unsaturated heterocyclic group containing 2 to 5 carbon atoms and 0 to 4 additional heteroatoms selected from the group consisting of nitrogen, oxygen, and $-SO_n-$ (where n is 0 to 2) wherein said saturated or unsaturated heterocyclic group is optionally fused with one or two ring(s) structures selected from the group consisting of cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl group to form a bi- or tri-fused ring system and further wherein said heterocyclic group and each of such ring structures are optionally substituted with 1 to 3 substituents selected from the group consisting of with one or two substituent(s) selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, substituted alkoxy, acyloxy, substituted acyloxy, amino, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, acylamino, substituted acylamino, N-acyl-N-alkylamino, substituted N-acyl-N-alkylamino, alkylene dioxy, (alkylsulfonyl)amino, substituted (alkylsulfonyl)amino, N-(alkylsulfonyl)-N-alkylamino, substituted N-(alkylsulfonyl)-N-alkylamino, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, cyano,

5 acyl, substituted acyl, carboxy, substituted carboxy, nitro, thiol, alkylthio, substituted alkylthio, alkylsulfoxy, substituted alkylsulfoxy, alkylsulfonyl, substituted alkylsulfonyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

10 R^2 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;

15 C is a group wherein W', together with $-C(=Z)N-$, forms a saturated or unsaturated heterocyclic group containing 2 to 5 carbon atoms and 0 to 4 additional heteroatoms selected from the group consisting of nitrogen, oxygen, and $-SO_n-$ (where n is 0 to 2) wherein said saturated or unsaturated heterocyclic group is optionally fused with one or two ring(s) structures selected from the group consisting of cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl group to form a bi- or tri-fused ring system and further wherein said heterocyclic group and each of such ring structures are
20 optionally substituted with 1 to 3 substituents selected from the group consisting of with one or two substituent(s) selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, substituted alkoxy, alkylendioxy, acyloxy, substituted acyloxy, amino, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, acylamino, substituted acylamino, N-acyl-N-alkylamino, substituted N-acyl-N-alkylamino,
25 (alkylsulfonyl)amino, substituted (alkylsulfonyl)amino, N-(alkylsulfonyl)-N-alkylamino, substituted N-(alkylsulfonyl)-N-alkylamino, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, cyano, nitro, acyl, substituted acyl, carboxy, substituted carboxy, thiol, alkylthio, substituted alkylthio, alkylsulfoxy, substituted alkylsulfoxy, alkylsulfonyl, substituted alkylsulfonyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

X is selected from the group consisting of hydroxyl, alkoxy,

09910702-072001

5 substituted alkoxy, alkenoxy, substituted alkenoxy, cycloalkoxy, substituted
cycloalkoxy, cycloalkenoxy, substituted cycloalkenoxy, aryloxy, substituted
aryloxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy,
substituted heterocyclyloxy and -NR¹R² where each R¹ is independently
10 selected from the group consisting of hydrogen, alkyl, substituted alkyl,
alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and
substituted heterocyclic;

and enantiomers, diastereomers and pharmaceutically acceptable salts
thereof;

15 and further wherein the compound of Formula I has a binding affinity
to VLA-4 as expressed by an IC₅₀ of about 15μM or less.

In a preferred embodiment, in compound (Ia), B is either:

(a) a group wherein W, together with -C(=Z)NR²- where Z is -O-,
20 forms an unsaturated heterocyclic group containing 3 or 4 carbon atoms and
0 or 1 additional nitrogen atoms and further wherein the unsaturated
heterocyclic group is optionally substituted, in addition to the R² group, with
1 or 2 substituents selected from the group consisting of alkyl, alkoxy,
substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono
25 or dialkylamino. Preferably B is 2-pyridone, (e.g., 2-pyridon-3-yl, 2-
pyridon-4-yl, etc.), or 6-pyrimidone (e.g., 6-pyrimidon-5-yl, etc.) that is
optionally substituted, in addition to the R² group, with 1 or 2 substituents
selected from the group consisting of alkyl, alkoxy, substituted alkoxy,
alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino,
30 more preferably methyl, ethyl, propyl, methoxy, ethoxy, propoxy, butoxy,
allyloxy, butenyloxy (wherein the methyl, ethyl, propyl, butyl, and allyl
group in said methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy may
be optionally substituted with one, two or three substituents selected from
the group consisting of hydroxy, alkoxy, thiol, alkylthio, alkylsulfoxide,

alkylsulfone, halo, alkylamino, dialkylamino, amino, aminoacyl, preferably, hydroxy, methoxy, ethoxy, methylthio, methylsulfane, methylsulfone, fluoro, methylamino, dimethylamino, amino, and acetylamino), chloro, bromo, hydroxy, methylamino, or dimethylamino. More preferably in the above rings R^2 is alkyl, preferably methyl; or

(b) a group wherein W, together with $-C(=Z)NR^2-$ where Z is -O-, forms a saturated or unsaturated heterocyclic group containing 3 or 4 carbon atoms and 0 or 1 additional nitrogen atoms wherein said saturated or unsaturated heterocyclic group is fused to a heterocyclic ring selected from the group consisting of dioxolane, dioxane, homodioxane, oxetane, tetrahydrofuran, dihydropyran, furan, oxazolidine, oxazole, isoxazole, oxazolidinone, oxathiolane, and 1,3-dioxolan-2-one and wherein the resulting fused ring is optionally substituted, in addition to the R^2 group, on any ring atom capable of substitution with 1 or 2 substituents selected from the group consisting of alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino. Preferably B is 2-pyridone or 6-pyrimidone that is fused to a heterocyclic ring selected from the group consisting of dioxolane, dioxane, homodioxane, oxetane, tetrahydrofuran, dihydropyran, furan, oxazolidine, oxazole, isoxazole, oxazolidinone, oxathiolane, and 1,3-dioxolan-2-one, and wherein the resulting fused ring is optionally substituted, in addition to the R^2 group, on any ring atom capable of substitution with 1 or 2 substituents selected from the group consisting of alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino, more preferably methyl, ethyl, propyl, methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy (wherein the methyl, ethyl, propyl, butyl, and allyl group in said methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy may be optionally substituted with one, two or three substituents selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, alkylsulfoxide, alkylsulfone, halo, alkylamino, dialkylamino, amino, aminoacyl, preferably,

5 hydroxy, methoxy, ethoxy, methylthio, methylsulfane, methylsulfone, fluoro, methylamino, dimethylamino, amino, and acetylamino), chloro, bromo, hydroxy, methylamino, or dimethylamino. More preferably in the above rings R^2 is alkyl, preferably methyl.

10 In a preferred embodiment, in compound (Ib), C is either:

(a) a group wherein W' , together with $-C(=Z)N-$ where Z is $-O-$, forms an unsaturated heterocyclic group containing 2 to 4 carbon atoms and 0 to 2 additional nitrogen atoms and further the wherein the unsaturated heterocyclic group is optionally substituted, in addition to the R^2 group, with 1 or 2 substituents selected from the group consisting of alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino. Preferably C is 2-pyridon-1-yl or 6-pyrimidon-1-yl that is optionally substituted, in addition to the R^2 group, with 1 or 2 substituents selected from the group consisting of alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino, more preferably methyl, ethyl, propyl, methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy (wherein the methyl, ethyl, propyl, butyl, and allyl group in said methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy may be optionally substituted with one, two or three substituents selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, alkylsulfoxide, alkylsulfone, halo, alkylamino, dialkylamino, amino, aminoacyl, preferably, hydroxy, methoxy, ethoxy, methylthio, methylsulfane, methylsulfone, fluoro, methylamino, dimethylamino, amino, and acetylamino), chloro, bromo, hydroxy, methylamino, or dimethylamino. More preferably in the above rings R^2 is alkyl, preferably methyl; or

(b) a group wherein W' , together with $-C(=Z)N-$ where Z is $-O-$, forms a saturated or unsaturated heterocyclic group containing 2 to 4 carbon atoms and 0 to 2 additional nitrogen atoms wherein said saturated or unsaturated heterocyclic group is fused to a heterocyclic ring selected from the group

5 consisting of dioxolane, dioxane, homodioxane, oxetane, tetrahydrofuran,
dihydropyran, furan, oxazolidine, oxazole, isoxazole, oxazolidinone,
oxathiolane, and 1,3-dioxolan-2-one and wherein the resulting fused ring is
optionally substituted, in addition to the R² group, on any ring atom capable
of substitution with 1 or 2 substituents selected from the group consisting of
10 alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo,
hydroxy, mono or dialkylamino. Preferably C is 2-pyridon-1-yl or 6-
pyrimidon-1-yl that is fused to a heterocyclic ring selected from the group
consisting of dioxolane, dioxane, homodioxane, oxetane, tetrahydrofuran,
dihydropyran, furan, oxazolidine, oxazole, isoxazole, oxazolidinone,
15 oxathiolane, and 1,3-dioxolan-2-one, and wherein the resulting fused ring is
optionally substituted, in addition to the R² group, on any ring atom capable
of substitution with 1 or 2 substituents selected from the group consisting of
alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo,
hydroxy, mono or dialkylamino, more preferably methyl, ethyl, propyl,
20 methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy (wherein the
methyl, ethyl, propyl, butyl, and allyl group in said methoxy, ethoxy,
propoxy, butoxy, allyloxy, butenyloxy may be optionally substituted with
one, two or three substituents selected from the group consisting of hydroxy,
alkoxy, thiol, alkylthio, alkylsulfoxide, alkylsulfone, halo, alkylamino,
25 dialkylamino, amino, aminoacyl, preferably, hydroxy, methoxy, ethoxy,
methylthio, methylsulfane, methylsulfone, fluoro, methylamino,
dimethylamino, amino, and acetylamino), chloro, bromo, hydroxy,
methylamino, or dimethylamino. More preferably in the above rings R² is
alkyl, preferably methyl.


30 In another preferred embodiment, Ar¹ in compounds (Ia) and (Ib) is a
heteroaryl group optionally substituted with 1 to 3 substituents selected from
the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy,
amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted

5 aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic
and halogen, preferably 1-oxo-1,2,5-thiadiazole, 1,1-dioxo-1,2,5-thiadiazole,
1,3,5-triazine, pyridazine, pyrimidine or pyrazine substituted with above
substituents; more preferably pyridazine, pyrimidine or pyrazine wherein the
pyridazine, pyrimidine or pyrazine ring is optionally substituted with 1 to 3
10 substituents selected from the group consisting of alkyl, substituted alkyl,
alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted
cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
heterocyclic, substituted heterocyclic and halogen.

15 In yet another preferred embodiment, Ar^2 in compounds (Ia) and (Ib)
is phenyl.


In the above preferred embodiments, a more preferred group of
compounds is that wherein X is hydroxyl and R^1 is hydrogen.

20 In yet another preferred embodiment, this invention is directed to
compounds of formula IIa, IIb, IIc, IId, or IIe:




5


10



15




20



25

30



09910702-072001

5 wherein

X is hydroxyl or alkoxy;

Ar² is an aryl or heteroaryl group optionally substituted, in addition to ring B, with one or two substituent(s) selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, substituted alkoxy, acyloxy, substituted acyloxy, amino, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, acylamino, substituted acylamino, N-acyl-N-alkylamino, substituted N-acyl-N-alkylamino, (alkylsulfonyl)amino, substituted (alkylsulfonyl)amino, N-(alkylsulfonyl)-N-alkylamino, substituted N-(alkylsulfonyl)-N-alkylamino, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, cyano, acyl, substituted acyl, carboxy, substituted carboxy, thiol, alkylthio, substituted alkylthio, alkylsulfoxy, substituted alkylsulfoxy, alkylsulfonyl, and substituted alkylsulfonyl;

R⁵ is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl;

R⁶ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and -SO₂R¹⁰ where R¹⁰ is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

R⁷ and R⁸ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen;

5 R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen; and

10 R¹⁸ is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

15 R²⁰ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen;

20 R²¹ is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclic and substituted heterocyclic;

b is 1 or 2; and

25 B is a group wherein W, together with -C(=Z)NR²-, forms a saturated or unsaturated heterocyclic group containing 2 to 5 carbon atoms and 0 to 4 additional heteroatoms selected from the group consisting of nitrogen, oxygen, and -SO_n- (where *n* is 0 to 2) wherein said saturated or unsaturated heterocyclic group is optionally fused with one or two ring(s) structures selected from the group consisting of cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl group to form a bi- or tri-fused ring system and further wherein said heterocyclic group and each of such ring structures
30 are optionally substituted with 1 to 3 substituents selected from the group consisting of with one or two substituent(s) selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, substituted alkoxy, acyloxy, substituted acyloxy, amino, alkylamino, substituted alkylamino, dialkylamino, substituted dialkylamino, acylamino, substituted acylamino,

5 N-acyl-N-alkylamino, substituted N-acyl-N-alkylamino, alkylene dioxy,
(alkylsulfonyl)amino, substituted (alkylsulfonyl)amino, N-(alkylsulfonyl)-N-
alkylamino, substituted N-(alkylsulfonyl)-N-alkylamino, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl,
cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, cyano,
10 acyl, substituted acyl, carboxy, substituted carboxy, nitro, thiol, alkylthio,
substituted alkylthio, alkylsulfoxy, substituted alkylsulfoxy, alkylsulfonyl,
substituted alkylsulfonyl, aryl, substituted aryl, heteroaryl, substituted
heteroaryl;

15 R^2 is selected from the group consisting of alkyl, substituted alkyl,
aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl,
substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl; and
and enantiomers, diastereomers and pharmaceutically acceptable salts
thereof.

20 Preferably, the compound is selected from formula IIc, IId or IIe.

In the above compounds II(a-e), B is either:

(a) a group wherein W, together with $-C(=Z)NR^2-$ where Z is -O-,
forms an unsaturated heterocyclic group containing 2 to 4 carbon atoms and
25 0 to 2 additional nitrogen atoms and further the wherein the unsaturated
heterocyclic group is optionally substituted, in addition to the R^2 group, with
1 or 2 substituents selected from the group consisting of alkyl, alkoxy,
substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono
or dialkylamino. Preferably B is 2-pyridone, (e.g., 2-pyridon-3-yl, 2-
30 pyridon-4-yl, etc.) or 6-pyrimidone (e.g., 6-pyrimidon-5-yl, etc.) that is
optionally substituted, in addition to the R^2 group, with 1 or 2 substituents
selected from the group consisting of alkyl, alkoxy, substituted alkoxy,
alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino,
more preferably methyl, ethyl, propyl, methoxy, ethoxy, propoxy, butoxy,

allyloxy, butenyloxy (wherein the methyl, ethyl, propyl, butyl, and allyl group in said methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy may be optionally substituted with one, two or three substituents selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, alkylsulfoxide, alkylsulfone, halo, alkylamino, dialkylamino, amino, aminoacyl, preferably, hydroxy, methoxy, ethoxy, methylthio, methylsulfane, methylsulfone, fluoro, methylamino, dimethylamino, amino, and acetylamino), chloro, bromo, hydroxy, methylamino, or dimethylamino. More preferably in the above rings R² is alkyl, preferably methyl; or

(b) a group wherein W, together with -C(=Z)NR²- where Z is -O-, forms a saturated or unsaturated heterocyclic group containing 2 to 4 carbon atoms and 0 to 2 additional nitrogen atoms wherein said saturated or unsaturated heterocyclic group is fused to a heterocyclic ring selected from the group consisting of dioxolane, dioxane, homodioxane, oxetane, tetrahydrofuran, dihydropyran, furan, oxazolidine, oxazole, isoxazole, oxazolidinone, oxathiolane, and 1,3-dioxolan-2-one and wherein the resulting fused ring is optionally substituted, in addition to the R² group, on any ring atom capable of substitution with 1 or 2 substituents selected from the group consisting of alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino. Preferably B is 2-pyridone or 6-pyrimidone that is fused to a heterocyclic ring selected from the group consisting of dioxolane, dioxane, homodioxane, oxetane, tetrahydrofuran, dihydropyran, furan, oxazolidine, oxazole, isoxazole, oxazolidinone, oxathiolane, and 1,3-dioxolan-2-one, and wherein the resulting fused ring is optionally substituted, in addition to the R² group, on any ring atom capable of substitution with 1 or 2 substituents selected from the group consisting of alkyl, alkoxy, substituted alkoxy, alkenyloxy, substituted alkenyloxy, halo, hydroxy, mono or dialkylamino, preferably methyl, ethyl, propyl, methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy (wherein the methyl, ethyl, propyl, butyl, and allyl group in said

methoxy, ethoxy, propoxy, butoxy, allyloxy, butenyloxy may be optionally substituted with one, two or three substituents selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, alkylsulfoxide, alkylsulfone, halo, alkylamino, dialkylamino, amino, aminoacyl, preferably, hydroxy, methoxy, ethoxy, methylthio, methylsulfane, methylsulfone, fluoro, methylamino, dimethylamino, amino, and acetylamino), chloro, bromo, hydroxy, methylamino, or dimethylamino. More preferably in the above rings R^2 is alkyl, preferably methyl and X is hydroxyl.

In the above compounds II(a-e), Ar^2 is preferably phenyl.

Within the above preferred groups of II(a-e), a more preferred group of compounds is that wherein R^5 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl. Even more preferably R^5 is selected from the group consisting of 4-methylphenyl, methyl, benzyl, *n*-butyl, *n*-hexyl, 4-chlorophenyl, 1-naphthyl, 2-naphthyl, 4-methoxyphenyl, phenyl, 2,4,6-trimethylphenyl, 2-(methoxycarbonyl)phenyl, 2-carboxyphenyl, 3,5-dichlorophenyl, 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 4-($CH_3C(O)NH$ -)phenyl, 4-trifluoromethoxyphenyl, 4-cyanophenyl, isopropyl, 3,5-di-(trifluoromethyl)phenyl, 4-*t*-butylphenyl, 4-*t*-butoxyphenyl, 4-nitrophenyl, 2-thienyl, 1-N-methyl-3-methyl-5-chloropyrazol-4-yl, phenethyl, 1-N-methylimidazol-4-yl, 4-bromophenyl, 4-amidinophenyl, 4-methylamidinophenyl, 4- $[CH_3SC(=NH)]$ phenyl, 5-chloro-2-thienyl, 2,5-dichloro-4-thienyl, 1-N-methyl-4-pyrazolyl, 2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 4- $[H_2NC(S)]$ phenyl, 4-aminophenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3,5-difluorophenyl, pyridin-3-yl, pyrimidin-2-yl, 4-(3'-dimethylamino-*n*-propoxy)-phenyl, and 1-methylpyrazol-4-yl;

R^{16} is substituted amino;

5 R⁶, R¹⁷ and/or R²⁰ are hydrogen; and
 R¹⁸ and/or R²¹ are alkyl, substituted alkyl, aryl, or substituted aryl.

10 In a second aspect, this invention provides pharmaceutical
compositions comprising a pharmaceutically acceptable carrier and a
therapeutically effective amount of the compounds defined herein.

15 In a third aspect, this invention is directed to a method for treating a
disease mediated by VLA-4 in a patient, which method comprises
administering a pharmaceutical composition comprising a pharmaceutically
acceptable carrier and a therapeutically effective amount of compounds
defined herein.

20 In the above compounds, when X is other than -OH or
pharmaceutical salts thereof, X is preferably a substituent which will convert
(e.g., hydrolyze, metabolize, etc.) *in vivo* to a compound where X is -OH or
a salt thereof. Accordingly, suitable X groups are any art recognized
pharmaceutically acceptable groups which will hydrolyze or otherwise
convert *in vivo* to a hydroxyl group or a salt thereof including, by way of
example, esters (X is alkoxy, substituted alkoxy, cycloalkoxy, substituted
25 cycloalkoxy, alkenoxy, substituted alkenoxy, cycloalkenox, substituted
cycloalkenox, aryloxy, substituted aryloxy, heteroaryloxy, substituted
heteroaryloxy, heterocycloxy, substituted heterocycloxy, and the like).

30 This invention also provides methods for binding VLA-4 in a
biological sample which method comprises contacting the biological sample
with a compound of this invention under conditions wherein said compound
binds to VLA-4.

09910702.072001


5 The compounds and pharmaceutical compositions of this invention
are useful for treating disease conditions mediated by VLA-4 or leucocyte
adhesion. Such disease conditions include, by way of example, asthma,
Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including
acute juvenile onset diabetes), inflammatory bowel disease (including
10 ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid
arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis,
stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis,
psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury
such as that which occurs in adult respiratory distress syndrome.

15 Other disease conditions include, but are not limited to, inflammatory
conditions such as erythema nodosum, allergic conjunctivitis, optic neuritis,
uveitis, allergic rhinitis, Ankylosing spondylitis, psoriatic arthritis,
vasculitis, Reiter's syndrome, systemic lupus erythematosus, progressive
20 systemic sclerosis, polymyositis, dermatomyositis, Wegner's
granulomatosis, aortitis, sarcoidosis, lymphocytopenia, temporal arteritis,
pericarditis, myocarditis, congestive heart failure, polyarteritis nodosa,
hypersensitivity syndromes, allergy, hypereosinophilic syndromes, Churg-
Strauss syndrome, chronic obstructive pulmonary disease, hypersensitivity
25 pneumonitis, chronic active hepatitis, interstitial cystitis, autoimmune
endocrine failure, primary biliary cirrhosis, autoimmune aplastic anemia,
chronic persistent hepatitis and thyroiditis.

30 In a preferred embodiment, the disease condition mediated by VLA-4
is an inflammatory disease.

 Preferred compounds of this invention include those set forth in the
Table below:

Table I



Cpd #	A	B
1	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-2-pyridon-3-yl
2	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-2-pyridon-3-yl
3	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-n-C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
4	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-i-C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
5	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-6-pyrimidon-5-yl
6	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-6-pyrimidon-5-yl
7	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-n-C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl
8	[2-(C ₂ H ₅) ₂ N-5-CF ₃ CH ₂]pyrimidin-4-yl	1-i-C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl
9	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-2-pyridon-3-yl

09910702 072001
T00220 2020T660

5

10	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-2-pyridon-3-yl
11	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-n-C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
12	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-i-C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
13	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-6-pyrimidon-5-yl
14	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-6-pyrimidon-5-yl
15	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-n-C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl
16	[2-(C ₂ H ₅) ₂ N-5-(CH ₃) ₂ CH]pyrimidin-4-yl	1-i-C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl
17	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	1-i-C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
18	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-2-pyridon-3-yl
19	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	1-n-C ₂ H ₅ -4-CH ₃ O-2-pyridon-3-yl
20	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	1-i-C ₂ H ₅ -4-CH ₃ O-2-pyridon-3-yl
21	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-6-pyrimidon-5-yl
22	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-6-pyrimidon-5-yl
23	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	1-n-C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl

10

15

24	[2-(C ₂ H ₅) ₂ N-5-(CH ₃ CH ₂) ₂ CH]- pyrimidin-4-yl	1- <i>i</i> -C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5- yl
25	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-2-pyridon-3-yl
26	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-2-pyridon-3-yl
27	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1- <i>n</i> -C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
28	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1- <i>i</i> -C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
29	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-6-pyrimidon-5-yl
30	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-6-pyrimidon-5-yl
31	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1- <i>n</i> -C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5- yl
32	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isoxazol-4- yl)]pyrimidin-4-yl	1- <i>i</i> -C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5- yl
33	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol- 4-yl)]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-2-pyridon-3-yl
34	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol- 4-yl)]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-2-pyridon-3-yl
35	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol- 4-yl)]pyrimidin-4-yl	1- <i>n</i> -C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
36	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol- 4-yl)]pyrimidin-4-yl	1- <i>i</i> -C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
37	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol- 4-yl)]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-6-pyrimidon-5-yl

38	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol-4-yl)]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-6-pyrimidon-5-yl
39	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol-4-yl)]pyrimidin-4-yl	1- <i>n</i> -C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl
40	[2-(C ₂ H ₅) ₂ N-5-(1,3,5-triCH ₃ pyrazol-4-yl)]pyrimidin-4-yl	1- <i>i</i> -C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl
41	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-2-pyridon-3-yl
42	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-2-pyridon-3-yl
43	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1- <i>n</i> -C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
44	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1- <i>i</i> -C ₃ H ₇ -4-CH ₃ O-2-pyridon-3-yl
45	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1-CH ₃ -4-CH ₃ O-6-pyrimidon-5-yl
46	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1-C ₂ H ₅ -4-CH ₃ O-6-pyrimidon-5-yl
47	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1- <i>n</i> -C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl
48	[2-(C ₂ H ₅) ₂ N-5-(3,5-diCH ₃ isothiazol-4-yl)]pyrimidin-4-yl	1- <i>i</i> -C ₃ H ₇ -4-CH ₃ O-6-pyrimidon-5-yl

and are named as follows:

N-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-2-pyridon-3-yl)phenylalanine;

N-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-2-pyridon-3-yl)phenylalanine;

- 5 *N*-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-
(1-propyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-
(1-isopropyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-
10 (1-methyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-
(1-ethyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-
(1-propyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- 15 *N*-(2-(*N,N*-diethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-
(1-isopropyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
methyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
20 ethyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
propyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
isopropyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- 25 *N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
methyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
ethyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
30 propyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-L-4'-(1-
isopropyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-
methyl-4-methoxy-2-pyridon-3-yl)phenylalanine;

09910702-072001

- 5 *N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- 10 *N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- 15 *N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- 20 *N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- 25 *N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- 30 *N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
- N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;

09910702-022001
F00220-2020T660

09910702-072001

- 5 *N*-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
10 *N*-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
15 *N*-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
20 *N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
25 *N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-2-pyridon-3-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
30 *N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-ethyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine;
 N-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-propyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine; and

5 *N*-(2-(*N,N*-diethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-4'-(1-isopropyl-4-methoxy-6-pyrimidon-5-yl)phenylalanine.

DETAILED DESCRIPTION OF THE INVENTION

As above, this invention relates to compounds which inhibit leukocyte
10 adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
However, prior to describing this invention in further detail, the following
terms will first be defined.

Definitions

15 As used herein, "alkyl" refers to alkyl groups preferably having from
1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is
exemplified by groups such as methyl, t-butyl, n-heptyl, octyl and the like.

"Substituted alkyl" refers to an alkyl group, preferably of from 1 to 10
20 carbon atoms, having from 1 to 5 substituents selected from the group
consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino,
acyloxy, amino, amidino, alkyl amidino, thioamidino, aminoacyl,
aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl,
substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted
25 aryloxyaryl, cyano, halogen, hydroxyl, nitro, carboxyl, carboxylalkyl,
carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted
cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl,
carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted
heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone,
30 thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl,
thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted
thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl,
substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy,
substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy,

heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, $-\text{OS}(\text{O})_2\text{-alkyl}$, $-\text{OS}(\text{O})_2\text{-substituted alkyl}$, $-\text{OS}(\text{O})_2\text{-aryl}$, $-\text{OS}(\text{O})_2\text{-substituted aryl}$, $-\text{OS}(\text{O})_2\text{-heteroaryl}$, $-\text{OS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{OS}(\text{O})_2\text{-heterocyclic}$, $-\text{OS}(\text{O})_2\text{-substituted heterocyclic}$, $-\text{OSO}_2\text{-NRR}$ where R is hydrogen or alkyl, $-\text{NRS}(\text{O})_2\text{-alkyl}$, $-\text{NRS}(\text{O})_2\text{-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-aryl}$, $-\text{NRS}(\text{O})_2\text{-substituted aryl}$, $-\text{NRS}(\text{O})_2\text{-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-substituted heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-alkyl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-NR-aryl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted aryl}$, $-\text{NRS}(\text{O})_2\text{-NR-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-NR-heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted heterocyclic}$ where R is hydrogen or alkyl, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-substituted arylamino, mono- and di-heteroarylamino, mono- and di-substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-substituted heterocyclic amino, unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and substituted alkyl groups having amino groups blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like or alkyl/substituted alkyl groups substituted with $-\text{SO}_2\text{-alkyl}$, $-\text{SO}_2\text{-substituted alkyl}$, $-\text{SO}_2\text{-alkenyl}$, $-\text{SO}_2\text{-substituted alkenyl}$, $-\text{SO}_2\text{-cycloalkyl}$, $-\text{SO}_2\text{-substituted cycloalkyl}$, $-\text{SO}_2\text{-aryl}$, $-\text{SO}_2\text{-substituted aryl}$, $-\text{SO}_2\text{-heteroaryl}$, $-\text{SO}_2\text{-substituted heteroaryl}$, $-\text{SO}_2\text{-heterocyclic}$, $-\text{SO}_2\text{-substituted heterocyclic}$ and $-\text{SO}_2\text{NRR}$ where R is hydrogen or alkyl.

"Alkoxy" refers to the group "alkyl-O-" which includes, by way of example, methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, *tert*-butoxy, *sec*-butoxy, *n*-pentoxy, *n*-hexoxy, 1,2-dimethylbutoxy, and the like.

"Substituted alkoxy" refers to the group "substituted alkyl-O-".

5 "Alkenoxy" refers to the group "alkenyl-O-".

"Substituted alkenoxy" refers to the group "substituted alkenyl-O-".

10 "Acyl" refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)-, cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O), heterocyclic-C(O)-, and substituted heterocyclic-C(O)- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

15 "Acylamino" refers to the group -C(O)NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where each R is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

20 "Thiocarbonylamino" refers to the group -C(S)NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where each

5 R is joined to form, together with the nitrogen atom a heterocyclic or substituted heterocyclic ring wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

10 "Acyloxy" refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, alkenyl-C(O)O-, substituted alkenyl-C(O)O-, alkynyl-C(O)O-, substituted alkynyl-C(O)O-, aryl-C(O)O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-C(O)O-, and substituted heterocyclic-C(O)O- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

20 "Oxysulfonyl" refers to the groups alkyl-SO₂O-, substituted alkyl-SO₂O-, alkenyl-SO₂O-, substituted alkenyl-SO₂O-, alkynyl-SO₂O-, substituted alkynyl-SO₂O-, aryl-SO₂O-, substituted aryl-SO₂O-, cycloalkyl-SO₂O-, substituted cycloalkyl-SO₂O-, heteroaryl-SO₂O-, substituted heteroaryl-SO₂O-, heterocyclic-SO₂O-, and substituted heterocyclic-SO₂O- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

30 "Alkenyl" refers to alkenyl group preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation.

5 "Substituted alkenyl" refers to alkenyl groups having from 1 to 5
substituents selected from the group consisting of alkoxy, substituted alkoxy,
acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino,
thioamidino, aminoacyl, aminocarbonylamino, aminothiocabonylamino,
aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy,
10 aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro,
carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl,
carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl,
carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic,
carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl,
15 guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl,
substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl,
substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic,
heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic,
cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted
20 heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,
oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-
substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl,
-OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted
heterocyclic, -OSO₂-NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl, -
25 NRS(O)₂-substituted alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -
NRS(O)₂-heteroaryl, -NRS(O)₂-substituted heteroaryl, -NRS(O)₂-heterocyclic,
-NRS(O)₂-substituted heterocyclic, -NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-
substituted alkyl, -NRS(O)₂-NR-aryl, -NRS(O)₂-NR-substituted aryl, -
NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-substituted heteroaryl, -NRS(O)₂-NR-
30 heterocyclic, -NRS(O)₂-NR-substituted heterocyclic where R is hydrogen or
alkyl, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino,
mono- and di-arylamino, mono- and di-substituted arylamino, mono- and di-
heteroarylamino, mono- and di-substituted heteroarylamino, mono- and di-
heterocyclic amino, mono- and di-substituted heterocyclic amino,

09910702-02660

5 unsymmetric di-substituted amines having different substituents selected from
alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted
heteroaryl, heterocyclic and substituted heterocyclic and substituted alkenyl
groups having amino groups blocked by conventional blocking groups such as
Boc, Cbz, formyl, and the like or alkenyl/substituted alkenyl groups
10 substituted with -SO₂-alkyl, -SO₂-substituted alkyl, -SO₂-alkenyl, -SO₂-
substituted alkenyl, -SO₂-cycloalkyl, -SO₂-substituted cycloalkyl, -SO₂-aryl, -
SO₂-substituted aryl, -SO₂-heteroaryl, -SO₂-substituted heteroaryl, -SO₂-
heterocyclic, -SO₂-substituted heterocyclic and -SO₂NRR where R is
hydrogen or alkyl.

15 "Alkynyl" refers to alkynyl group preferably having from 2 to 10
carbon atoms and more preferably 3 to 6 carbon atoms and having at least 1
and preferably from 1-2 sites of alkynyl unsaturation.

20 "Substituted alkynyl" refers to alkynyl groups having from 1 to 5
substituents selected from the group consisting of alkoxy, substituted alkoxy,
acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino,
thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino,
aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy,
25 aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro,
carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl,
carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl,
carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic,
carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl,
30 guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl,
substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl,
substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic,
heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic,
cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted

heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,
oxycarbonylamino, oxythiocarbonylamino, $-\text{OS}(\text{O})_2\text{-alkyl}$, $-\text{OS}(\text{O})_2\text{-}$
substituted alkyl, $-\text{OS}(\text{O})_2\text{-aryl}$, $-\text{OS}(\text{O})_2\text{-substituted aryl}$, $-\text{OS}(\text{O})_2\text{-heteroaryl}$,
 $-\text{OS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{OS}(\text{O})_2\text{-heterocyclic}$, $-\text{OS}(\text{O})_2\text{-substituted}$
heterocyclic, $-\text{OSO}_2\text{-NRR}$ where R is hydrogen or alkyl, $-\text{NRS}(\text{O})_2\text{-alkyl}$,
 $-\text{NRS}(\text{O})_2\text{-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-aryl}$, $-\text{NRS}(\text{O})_2\text{-substituted aryl}$,
 $-\text{NRS}(\text{O})_2\text{-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-}$
heterocyclic, $-\text{NRS}(\text{O})_2\text{-substituted heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-alkyl}$,
 $-\text{NRS}(\text{O})_2\text{-NR-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-NR-aryl}$,
 $-\text{NRS}(\text{O})_2\text{-NR-substituted aryl}$, $-\text{NRS}(\text{O})_2\text{-NR-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-NR-}$
substituted heteroaryl, $-\text{NRS}(\text{O})_2\text{-NR-heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted}$
heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono-
and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-
substituted arylamino, mono- and di-heteroarylamino, mono- and di-
substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-
substituted heterocyclic amino, unsymmetric di-substituted amines having
different substituents selected from alkyl, substituted alkyl, aryl, substituted
aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted
heterocyclic and substituted alkynyl groups having amino groups blocked by
conventional blocking groups such as Boc, Cbz, formyl, and the like or
alkynyl/substituted alkynyl groups substituted with $-\text{SO}_2\text{-alkyl}$, $-\text{SO}_2\text{-}$
substituted alkyl, $-\text{SO}_2\text{-alkenyl}$, $-\text{SO}_2\text{-substituted alkenyl}$, $-\text{SO}_2\text{-cycloalkyl}$,
 $-\text{SO}_2\text{-substituted cycloalkyl}$, $-\text{SO}_2\text{-aryl}$, $-\text{SO}_2\text{-substituted aryl}$, $-\text{SO}_2\text{-heteroaryl}$,
 $-\text{SO}_2\text{-substituted heteroaryl}$, $-\text{SO}_2\text{-heterocyclic}$, $-\text{SO}_2\text{-substituted heterocyclic}$
and $-\text{SO}_2\text{NRR}$ where R is hydrogen or alkyl.

"Amidino" refers to the group $\text{H}_2\text{NC}(=\text{NH})\text{-}$ and the term
"alkylamidino" refers to compounds having 1 to 3 alkyl groups (e.g.,
 $\text{alkylHNC}(=\text{NH})\text{-}$).

5 "Thioamidino" refers to the group RSC(=NH)- where R is hydrogen or alkyl.

"Amino" refers to the group -NH_2 .

10 "Substituted amino" refers to the group -NRR , where each R group is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, $\text{-SO}_2\text{-alkyl}$,
15 $\text{-SO}_2\text{-substituted alkyl}$, $\text{-SO}_2\text{-alkenyl}$, $\text{-SO}_2\text{-substituted alkenyl}$, $\text{-SO}_2\text{-cycloalkyl}$, $\text{-SO}_2\text{-substituted cycloalkyl}$, $\text{-SO}_2\text{-aryl}$, $\text{-SO}_2\text{-substituted aryl}$, $\text{-SO}_2\text{-heteroaryl}$, $\text{-SO}_2\text{-substituted heteroaryl}$, $\text{-SO}_2\text{-heterocyclic}$, $\text{-SO}_2\text{-substituted heterocyclic}$, provided that both R groups are not hydrogen; or the R groups can be joined together with the nitrogen atom to form a heterocyclic or substituted heterocyclic ring.

20 "Aminoacyl" refers to the groups -NRC(O)alkyl , $\text{-NRC(O)substituted alkyl}$, -NRC(O)cycloalkyl , $\text{-NRC(O)substituted cycloalkyl}$, -NRC(O)alkenyl , $\text{-NRC(O)substituted alkenyl}$, -NRC(O)alkynyl ,
25 $\text{-NRC(O)substituted alkynyl}$, -NRC(O)aryl , $\text{-NRC(O)substituted aryl}$, -NRC(O)heteroaryl , $\text{-NRC(O)substituted heteroaryl}$, $\text{-NRC(O)heterocyclic}$, and $\text{-NRC(O)substituted heterocyclic}$ where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl,
30 heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aminosulfonyl" refers to the groups $\text{-NRSO}_2\text{alkyl}$, $\text{-NRSO}_2\text{substituted alkyl}$, $\text{-NRSO}_2\text{cycloalkyl}$, $\text{-NRSO}_2\text{substituted cycloalkyl}$,

09910702 072001

5 -NRSO₂alkenyl, -NRSO₂substituted alkenyl, -NRSO₂alkynyl,
-NRSO₂substituted alkynyl, -NRSO₂aryl, -NRSO₂substituted aryl,
-NRSO₂heteroaryl, -NRSO₂substituted heteroaryl, -NRSO₂heterocyclic, and
-NRSO₂substituted heterocyclic where R is hydrogen or alkyl and wherein
10 alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined
herein.

"Aminocarbonyloxy" refers to the groups -NRC(O)O-alkyl,
15 -NRC(O)O-substituted alkyl, -NRC(O)O-alkenyl, -NRC(O)O-substituted
alkenyl, -NRC(O)O-alkynyl, -NRC(O)O-substituted alkynyl, -NRC(O)O-
cycloalkyl, -NRC(O)O-substituted cycloalkyl, -NRC(O)O-aryl, -NRC(O)O-
substituted aryl, -NRC(O)O-heteroaryl, -NRC(O)O-substituted heteroaryl,
-NRC(O)O-heterocyclic, and -NRC(O)O-substituted heterocyclic where R is
20 hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and
substituted heterocyclic are as defined herein.

25 "Aminosulfonyloxy" refers to the groups -NRSO₂O-alkyl,
-NRSO₂O-substituted alkyl, -NRSO₂O-alkenyl, -NRSO₂O-substituted alkenyl,
-NRSO₂O-alkynyl, -NRSO₂O-substituted alkynyl, -NRSO₂O-cycloalkyl,
-NRSO₂O-substituted cycloalkyl, -NRSO₂O-aryl, -NRSO₂O-substituted aryl,
-NRSO₂O-heteroaryl, -NRSO₂O-substituted heteroaryl,
30 -NRSO₂O-heterocyclic, and -NRSO₂O-substituted heterocyclic where R is
hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and
substituted heterocyclic are as defined herein.

"Oxycarbonylamino" refers to the groups -OC(O)NH₂, -OC(O)NRR, -OC(O)NR-alkyl, -OC(O)NR-substituted alkyl, -OC(O)NR-alkenyl, -OC(O)NR-substituted alkenyl, -OC(O)NR-alkynyl, -OC(O)NR-substituted alkynyl, -OC(O)NR-cycloalkyl, -OC(O)NR-substituted cycloalkyl, -OC(O)NR-aryl, -OC(O)NR-substituted aryl, -OC(O)NR-heteroaryl, -OC(O)NR-substituted heteroaryl, -OC(O)NR-heterocyclic, and -OC(O)NR-substituted heterocyclic where R is hydrogen, alkyl or where each R is joined to form, together with the nitrogen atom a heterocyclic or substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Oxythiocarbonylamino" refers to the groups -OC(S)NH₂, -OC(S)NRR, -OC(S)NR-alkyl, -OC(S)NR-substituted alkyl, -OC(S)NR-alkenyl, -OC(S)NR-substituted alkenyl, -OC(S)NR-alkynyl, -OC(S)NR-substituted alkynyl, -OC(S)NR-cycloalkyl, -OC(S)NR-substituted cycloalkyl, -OC(S)NR-aryl, -OC(S)NR-substituted aryl, -OC(S)NR-heteroaryl, -OC(S)NR-substituted heteroaryl, -OC(S)NR-heterocyclic, and -OC(S)NR-substituted heterocyclic where R is hydrogen, alkyl or where each R is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Oxysulfonylamino" refers to the groups -OSO₂NH₂, -OSO₂NRR, -OSO₂NR-alkyl, -OSO₂NR-substituted alkyl, -OSO₂NR-alkenyl, -OSO₂NR-substituted alkenyl, -OSO₂NR-alkynyl, -OSO₂NR-substituted alkynyl, -OSO₂NR-cycloalkyl, -OSO₂NR-substituted cycloalkyl,

5 -OSO₂NR-aryl, -OSO₂NR-substituted aryl, -OSO₂NR-heteroaryl,
-OSO₂NR-substituted heteroaryl, -OSO₂NR-heterocyclic, and
-OSO₂NR-substituted heterocyclic where R is hydrogen, alkyl or where each
R is joined to form, together with the nitrogen atom a heterocyclic or
substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl,
10 substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted
cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
heterocyclic and substituted heterocyclic are as defined herein.

"Aminocarbonylamino" refers to the groups -NRC(O)NRR,
15 -NRC(O)NR-alkyl, -NRC(O)NR-substituted alkyl, -NRC(O)NR-alkenyl,
-NRC(O)NR-substituted alkenyl, -NRC(O)NR-alkynyl,
-NRC(O)NR-substituted alkynyl, -NRC(O)NR-aryl, -NRC(O)NR-substituted
aryl, -NRC(O)NR-cycloalkyl, -NRC(O)NR-substituted cycloalkyl,
-NRC(O)NR-heteroaryl, and -NRC(O)NR-substituted heteroaryl,
20 -NRC(O)NR-heterocyclic, and -NRC(O)NR-substituted heterocyclic where
each R is independently hydrogen, alkyl or where each R is joined to form
together with the nitrogen atom a heterocyclic or substituted heterocyclic ring
as well as where one of the amino groups is blocked by conventional blocking
groups such as Boc, Cbz, formyl, and the like and wherein alkyl, substituted
25 alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,
substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted
heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aminothiocabonylamino" refers to the groups -NRC(S)NRR,
30 -NRC(S)NR-alkyl, -NRC(S)NR-substituted alkyl, -NRC(S)NR-alkenyl,
-NRC(S)NR-substituted alkenyl, -NRC(S)NR-alkynyl, -NRC(S)NR-
substituted alkynyl, -NRC(S)NR-aryl, -NRC(S)NR-substituted aryl,
-NRC(S)NR-cycloalkyl, -NRC(S)NR-substituted cycloalkyl, -NRC(S)NR-
heteroaryl, and -NRC(S)NR-substituted heteroaryl, -NRC(S)NR-heterocyclic,

09910702 "072001
T00270" 20107660

5 and -NRC(S)NR-substituted heterocyclic where each R is independently
hydrogen, alkyl or where each R is joined to form together with the nitrogen
atom a heterocyclic or substituted heterocyclic ring as well as where one of
the amino groups is blocked by conventional blocking groups such as Boc,
Cbz, formyl, and the like and wherein alkyl, substituted alkyl, alkenyl,
10 substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted
cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
heterocyclic and substituted heterocyclic are as defined herein.

"Aminosulfonylamino" refers to the groups -NRSO₂NRR,
15 -NRSO₂NR-alkyl, -NRSO₂NR-substituted alkyl, -NRSO₂NR-alkenyl,
-NRSO₂NR-substituted alkenyl, -NRSO₂NR-alkynyl,
-NRSO₂NR-substituted alkynyl, -NRSO₂NR-aryl, -NRSO₂NR-substituted
aryl, -NRSO₂NR-cycloalkyl, -NRSO₂NR-substituted cycloalkyl,
-NRSO₂NR-heteroaryl, and -NRSO₂NR-substituted heteroaryl,
20 -NRSO₂NR-heterocyclic, and -NRSO₂NR-substituted heterocyclic, where
each R is independently hydrogen, alkyl or where each R is joined to form
together with the nitrogen atom a heterocyclic or substituted heterocyclic ring
as well as where one of the amino groups is blocked by conventional blocking
groups such as Boc, Cbz, formyl, and the like and wherein alkyl, substituted
25 alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,
substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted
heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aryl" or "Ar" refers to an unsaturated aromatic carbocyclic group of
30 from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple
condensed rings (e.g., naphthyl or anthryl) which condensed rings may or
may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)-one-
7yl, and the like). Preferred aryls include phenyl and naphthyl.

Substituted aryl refers to aryl groups which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocabonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, $-S(O)_2$ -alkyl, $-S(O)_2$ -substituted alkyl, $-S(O)_2$ -cycloalkyl, $-S(O)_2$ -substituted cycloalkyl, $-S(O)_2$ -alkenyl, $-S(O)_2$ -substituted alkenyl, $-S(O)_2$ -aryl, $-S(O)_2$ -substituted aryl, $-S(O)_2$ -heteroaryl, $-S(O)_2$ -substituted heteroaryl, $-S(O)_2$ -heterocyclic, $-S(O)_2$ -substituted heterocyclic, $-OS(O)_2$ -alkyl, $-OS(O)_2$ -substituted alkyl, $-OS(O)_2$ -aryl, $-OS(O)_2$ -substituted aryl, $-OS(O)_2$ -heteroaryl, $-OS(O)_2$ -substituted heteroaryl, $-OS(O)_2$ -heterocyclic, $-OS(O)_2$ -substituted heterocyclic, $-OSO_2$ -NRR where R is hydrogen or alkyl, $-NRS(O)_2$ -alkyl, $-NRS(O)_2$ -substituted alkyl, $-NRS(O)_2$ -aryl, $-NRS(O)_2$ -substituted aryl, $-NRS(O)_2$ -heteroaryl, $-NRS(O)_2$ -substituted heteroaryl, $-NRS(O)_2$ -heterocyclic, $-NRS(O)_2$ -substituted heterocyclic, $-NRS(O)_2$ -NR-alkyl, $-NRS(O)_2$ -NR-substituted alkyl, $-NRS(O)_2$ -NR-aryl,

5 -NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-substituted arylamino, mono- and di-heteroarylamino, mono- and di-substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-substituted heterocyclic amino, unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and amino groups on the substituted aryl blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like or substituted with -SO₂NRR where R is hydrogen or alkyl.

"Aryloxy" refers to the group aryl-O- which includes, by way of example, phenoxy, naphthoxy, and the like.

"Substituted aryloxy" refers to substituted aryl-O- groups.

"Aryloxyaryl" refers to the group -aryl-O-aryl.

25 "Substituted aryloxyaryl" refers to aryloxyaryl groups substituted with from 1 to 3 substituents on either or both aryl rings selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocabonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-

5 substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl,
carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic,
carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl,
substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted
thioheteroaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic,
10 substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino,
guanidinosulfone, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic,
substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy,
substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,
oxycarbonylamino, oxythiocarbonylamino, -S(O)₂-alkyl, -S(O)₂-substituted
15 alkyl, -S(O)₂-cycloalkyl, -S(O)₂-substituted cycloalkyl, -S(O)₂-alkenyl, -S(O)₂-
substituted alkenyl, -S(O)₂-aryl, -S(O)₂-substituted aryl, -S(O)₂-heteroaryl, -
S(O)₂-substituted heteroaryl, -S(O)₂-heterocyclic, -S(O)₂-substituted
heterocyclic, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-
substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-
20 heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-NRR where R is
hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted alkyl, -NRS(O)₂-
aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl, -NRS(O)₂-substituted
heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted heterocyclic, -
NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl, -
25 NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-
substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted
heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono-
and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-
substituted arylamino, mono- and di-heteroarylamino, mono- and di-
30 substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-
substituted heterocyclic amino, unsymmetric di-substituted amines having
different substituents selected from alkyl, substituted alkyl, aryl, substituted
aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted
heterocyclic and amino groups on the substituted aryl blocked by conventional

09910702.072001

5 blocking groups such as Boc, Cbz, formyl, and the like or substituted with -
SO₂NRR where R is hydrogen or alkyl.

"Cycloalkyl" refers to cyclic alkyl groups of from 3 to 8 carbon atoms
having a single cyclic ring including, by way of example, cyclopropyl,
10 cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl and the like. Excluded from
this definition are multi-ring alkyl groups such as adamantanyl, etc.

"Cycloalkenyl" refers to cyclic alkenyl groups of from 3 to 8 carbon
atoms having single or multiple unsaturation but which are not aromatic.

15 "Substituted cycloalkyl" and "substituted cycloalkenyl" refer to a
cycloalkyl and cycloalkenyl groups, preferably of from 3 to 8 carbon atoms,
having from 1 to 5 substituents selected from the group consisting of oxo
(=O), thioxo (=S), alkoxy, substituted alkoxy, acyl, acylamino,
20 thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino,
aminoacyl, aminocarbonylamino, aminothiocarbonylamino,
aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy,
aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro,
carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl,
25 carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl,
carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic,
carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl,
guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl,
substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl,
30 substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic,
heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic,
cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted
heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,
oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-

000220-20201660

5 substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl,
-OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted
heterocyclic, -OSO₂-NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl,
-NRS(O)₂-substituted alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl,
-NRS(O)₂-heteroaryl, -NRS(O)₂-substituted heteroaryl,
10 -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted heterocyclic,
-NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl,
-NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-
substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted
heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono-
15 and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-
substituted arylamino, mono- and di-heteroarylamino, mono- and di-
substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-
substituted heterocyclic amino, unsymmetric di-substituted amines having
different substituents selected from alkyl, substituted alkyl, aryl, substituted
20 aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted
heterocyclic and substituted alkynyl groups having amino groups blocked by
conventional blocking groups such as Boc, Cbz, formyl, and the like or
alkynyl/substituted alkynyl groups substituted with -SO₂-alkyl, -SO₂-
substituted alkyl, -SO₂-alkenyl, -SO₂-substituted alkenyl, -SO₂-cycloalkyl,
25 -SO₂-substituted cycloalkyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl,
-SO₂-substituted heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic
and -SO₂NRR where R is hydrogen or alkyl.

"Cycloalkoxy" refers to -O-cycloalkyl groups.

"Substituted cycloalkoxy" refers to -O-substituted cycloalkyl groups.

"Cycloalkenoxy" refers to -O-cycloalkenyl groups.

5 "Substituted cycloalkenoxy" refers to -O-substituted cycloalkenyl groups.

"Guanidino" refers to the groups -NRC(=NR)NRR,
-NRC(=NR)NR-alkyl, -NRC(=NR)NR-substituted alkyl, -NRC(=NR)NR-
10 alkenyl, -NRC(=NR)NR-substituted alkenyl, -NRC(=NR)NR-alkynyl,
-NRC(=NR)NR-substituted alkynyl, -NRC(=NR)NR-aryl,
-NRC(=NR)NR-substituted aryl, -NRC(=NR)NR-cycloalkyl,
-NRC(=NR)NR-heteroaryl, -NRC(=NR)NR-substituted heteroaryl,
-NRC(=NR)NR-heterocyclic, and -NRC(=NR)NR-substituted heterocyclic
15 where each R is independently hydrogen and alkyl as well as where one of the
amino groups is blocked by conventional blocking groups such as Boc, Cbz,
formyl, and the like and wherein alkyl, substituted alkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and
20 substituted heterocyclic are as defined herein.

"Guanidinosulfone" refers to the groups -NRC(=NR)NRSO₂-alkyl,
-NRC(=NR)NRSO₂-substituted alkyl, -NRC(=NR)NRSO₂-alkenyl,
-NRC(=NR)NRSO₂-substituted alkenyl, -NRC(=NR)NRSO₂-alkynyl,
25 -NRC(=NR)NRSO₂-substituted alkynyl, -NRC(=NR)NRSO₂-aryl,
-NRC(=NR)NRSO₂-substituted aryl, -NRC(=NR)NRSO₂-cycloalkyl,
-NRC(=NR)NRSO₂-substituted cycloalkyl, -NRC(=NR)NRSO₂-heteroaryl,
and -NRC(=NR)NRSO₂-substituted heteroaryl, -NRC(=NR)NRSO₂-
heterocyclic, and -NRC(=NR)NRSO₂-substituted heterocyclic where each R
30 is independently hydrogen and alkyl and wherein alkyl, substituted alkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,
substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted
heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

0910702.072001

5 "Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and preferably is either chloro or bromo.

10 "Heteroaryl" refers to an aromatic carbocyclic group of from 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within the ring or oxides thereof. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indoliziny1 or benzothienyl). Additionally, the heteroatoms of the heteroaryl group may be oxidized, i.e., to form pyridine N-oxides or 1,1-dioxo-1,2,5-thiadiazoles and the like. Preferred heteroaryls include pyridyl, pyrrolyl, 15 indolyl, furyl, pyridaziny1, pyrimidinyl, pyraziny1, 1-oxo-1,2,5-thiadiazolyl and 1,1-dioxo-1,2,5-thiadiazolyl. The term "heteroaryl having two nitrogen atoms in the heteroaryl ring" refers to a heteroaryl group having two, and only two, nitrogen atoms in the heteroaryl ring and optionally containing 1 or 2 other heteroatoms in the heteroaryl ring, such as oxygen or sulfur

20 "Substituted heteroaryl" refers to heteroaryl groups which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, 25 substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocabonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, 30 carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl, substituted

09910702-072001

5 thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic, cycloalkyl,
substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro, heteroaryl,
substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy,
substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy,
heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino,
10 oxythiocarbonylamino, -S(O)₂-alkyl, -S(O)₂-substituted alkyl, -S(O)₂-
cycloalkyl, -S(O)₂-substituted cycloalkyl, -S(O)₂-alkenyl, -S(O)₂-substituted
alkenyl, -S(O)₂-aryl, -S(O)₂-substituted aryl, -S(O)₂-heteroaryl, -S(O)₂-
substituted heteroaryl, -S(O)₂-heterocyclic, -S(O)₂-substituted heterocyclic,
-OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted
15 aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-
heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-NRR where R is
hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted alkyl, -NRS(O)₂-
aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl, -NRS(O)₂-substituted
heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted heterocyclic,
20 -NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl, -
NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-
substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted
heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono-
and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-
25 substituted arylamino, mono- and di-heteroarylamino, mono- and di-
substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-
substituted heterocyclic amino, unsymmetric di-substituted amines having
different substituents selected from alkyl, substituted alkyl, aryl, substituted
aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted
30 heterocyclic and amino groups on the substituted aryl blocked by conventional
blocking groups such as Boc, Cbz, formyl, and the like or substituted with -
SO₂NRR where R is hydrogen or alkyl.

5 "Heteroaryloxy" refers to the group -O-heteroaryl and "substituted heteroaryloxy" refers to the group -O-substituted heteroaryl.

10 "Heterocycle" or "heterocyclic" refers to a saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more of the rings can be aryl or heteroaryl.

15 "Substituted heterocyclic" refers to heterocycle groups which are substituted with from 1 to 3 substituents selected from the group consisting of oxo (=O), thioxo (=S), alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, 20 aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, 25 guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted 30 heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl,

09910702-072001

5 -NRS(O)₂-substituted alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl,
-NRS(O)₂-heteroaryl, -NRS(O)₂-substituted heteroaryl,
-NRS(O)₂-heterocyclic, -NRS(O)₂-substituted heterocyclic,
-NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl,
-NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-
10 substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted
heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono-
and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-
substituted arylamino, mono- and di-heteroarylamino, mono- and di-
15 substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-
substituted heterocyclic amino, unsymmetric di-substituted amines having
different substituents selected from alkyl, substituted alkyl, aryl, substituted
aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted
heterocyclic and substituted alkynyl groups having amino groups blocked by
conventional blocking groups such as Boc, Cbz, formyl, and the like or
20 alkynyl/substituted alkynyl groups substituted with -SO₂-alkyl, -SO₂-
substituted alkyl, -SO₂-alkenyl, -SO₂-substituted alkenyl, -SO₂-cycloalkyl,
-SO₂-substituted cycloalkyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl,
-SO₂-substituted heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic
and -SO₂NRR where R is hydrogen or alkyl.

25 Examples of heterocycles and heteroaryls include, but are not limited
to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine,
pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine,
quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine,
30 quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline,
phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole,
phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine,
piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-
tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene,

5 benzo[b]thiophene, morpholino, thiomorpholino, piperidinyl, pyrrolidine, tetrahydrofuranyl, and the like.

"Heterocyclyloxy" refers to the group -O-heterocyclic and "substituted heterocyclyloxy" refers to the group -O-substituted heterocyclic.

10

"Thiol" refers to the group -SH.

"Thioalkyl" or "alkylthio" refers to the groups -S-alkyl

15

"Substituted thioalkyl" refers to the group -S-substituted alkyl.

"Alkylsulfoxy" refers to the group -SO-alkyl.

"Substituted alkylsulfoxy" refers to the group -SO-substituted alkyl.

20

"Alkylsulfonyl" refers to the group -SO₂-alkyl.

"Substituted alkylsulfonyl" refers to the group -SO₂-substituted alkyl.

25

"Thiocycloalkyl" refers to the groups -S-cycloalkyl.

"Substituted thiocycloalkyl" refers to the group -S-substituted cycloalkyl.

30

"Thioaryl" refers to the group -S-aryl and "substituted thioaryl" refers to the group -S-substituted aryl.

"Thioheteroaryl" refers to the group -S-heteroaryl and "substituted thioheteroaryl" refers to the group -S-substituted heteroaryl.

09910702-072001

5 "Thioheterocyclic" refers to the group -S-heterocyclic and "substituted thioheterocyclic" refers to the group -S-substituted heterocyclic.

"Alkylamino" or "substituted alkylamino" refers to the group -NHR wherein R is alkyl or substituted alkyl groups respectively as defined above.

10 "Dialkylamino" or "substituted dialkylamino" refers to the group -NRR wherein each R is alkyl or substituted alkyl groups respectively as defined above.

15 "Alkylsulfonylamino" or "substituted alkylsulfonylamino" refers to the group -NHSO₂R wherein R is alkyl or substituted alkyl groups respectively as defined above.

"N-Alkylsulfonyl-N-alkylamino" refers to the group -NRSO₂R^a wherein R and R^a are independently alkyl wherein alkyl is as defined above.

20 "Substituted N-alkylsulfonyl-N-alkylamino" refers to the group -NRSO₂R^a wherein R and R^a are independently alkyl or substituted alkyl groups wherein substituted alkyl is as defined above.

25 "Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound of Formula I which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule
30 contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

09910702-072001

5


10

15

25

30


In a preferred method of synthesis, the compounds, (Ia) or (Ib) of this invention are prepared by coupling an amino acid derivative of the formula (a) or (b) respectively:



where Ar^2 , ring B, C, R^1 , R^2 are as defined herein and P^1 is a carboxylic acid protecting group (such as an alkyl group, i.e. methyl, ethyl and the like), with a suitably functionalized heteroaryl or heterocyclic intermediate. For example, such coupling reactions may be performed by displacing a leaving group, such as chloro, bromo, iodo, tosyl and the like, from the heteroaryl or heterocyclic intermediate with the amino group of the amino acid derivative; or by reductive alkylation of the amino group of amino acid derivative with a carbonyl-functionalized intermediate. Such coupling reactions are well-known to those skilled in the art.

By way of illustration, the synthesis of a representative compound of formula Ia is shown in Scheme 1.

Scheme 1



5

As shown in Scheme 1, 5-nitrouracil, **1**, (commercially available from Aldrich Chemical Company, Milwaukee, Wisconsin USA) is treated with phosphorus oxychloride and *N,N*-dimethylaniline according to the procedure described in Whittaker, *J. Chem. Soc.* **1951**, 1565 to give 1,3-dichloro-4-nitropyrimidine, **2**.

10

09910702-072001

5 1,3-Dichloro-4-nitropyrimidine, **2**, is then reacted with about one
molar equivalent of an amino acid derivative of the formula (a) or (b) shown
above in the presence of a trialkylamine, such as diisopropylethylamine
(DIEA). Typically, this reaction is conducted in an inert diluent, such as
dichloromethane, at a temperature ranging from about 0°C to about 10°C for
10 about 5 min. to about 6 hours to afford intermediate **3** where X is -OP¹.

 The nitro group of intermediate **3** is then reduced using a conventional
reducing agent, such as hydrogen and a palladium on carbon catalyst. When
hydrogen and palladium on carbon are employed as the reducing agent, the
15 chloro group of intermediate **3** is also removed. This reaction is typically
conducted by contacting **3** with a Degussa-type palladium on carbon catalyst
(typically 20%) and excess sodium bicarbonate in an inert diluent, such as
methanol, under hydrogen (typically about 55 psi) for about 12 to 36 hours at
ambient temperature to afford amino intermediate **4**.

20 Amino intermediate **4** is then reacted with a sulfonyl chloride of the
formula: R⁵-S(O)₂-Cl, where R⁵ is as defined herein, to provide sulfonamide
intermediate **5**. This reaction is typically conducted by reacting the amino
intermediate **4** with at least one equivalent, preferably about 1.1 to about 2
25 equivalents, of the sulfonyl chloride in an inert diluent such as
dichloromethane and the like. Generally, the reaction is conducted at a
temperature ranging from about -70°C to about 40°C for about 1 to about 24
hours. Preferably, this reaction is conducted in the presence of a suitable
base to scavenge the acid generated during the reaction. Suitable bases
30 include, by way of example, tertiary amines, such as triethylamine,
diisopropylethylamine, *N*-methylmorpholine and the like. Alternatively, the
reaction can be conducted under Schotten-Baumann-type conditions using
aqueous alkali, such as sodium hydroxide and the like, as the base. Upon
completion of the reaction, the resulting sulfonamide **5** is recovered by

09910702-072001

5 conventional methods including neutralization, extraction, precipitation,
chromatography, filtration, and the like.

10 Other heteroaryl intermediates may also be employed in the above
described reactions including, but not limited to, 2-chloro-3-nitropyrazine (*J.*
Med. Chem. **1984**, 27, 1634); 4-chloro-5-nitroimidazole (*J. Chem. Soc.* **1930**,
268); and the like.

15 The amino acid derivatives (a) or (b), employed in the above reactions
can be prepared from known amino acids or by known methods for the
preparation of amino acids. For example, amino acid derivatives (a) or (b)
where Ar¹ is aryl, specifically phenyl, can be prepared from commercially
available 4'-iodophenylalanine (Aldrich) as follows. 4'-Iodophenylalanine is
first converted in two steps to give N-*tert*-butoxycarbonyl-4'-
iodophenylalanine methyl ester (*see.*, *J. Am. Chem. Soc.* **1992**, 114(19),
20 7597-7598). The latter compound is then reacted with a suitably substituted
(trialkylstannyl)-heterocycle (*see.*, *J. Org. Chem.* **1994**, 59(20), 5905-5911)
or a suitably substituted (dihydroxyboronyl)heterocycle (*see.*, *Tet. Lett.* **1993**,
34(13), 2127-2130), utilizing a palladium catalyst to form a carbon-carbon
bond, to give an N-*tert*-butoxycarbonyl-4'-(heterocyclyl)-phenylalanine
25 methyl ester. (A detailed description of the synthesis of N-*tert*-
butoxycarbonyl-4-(1-methyl-4-methoxypyridin-2-one-3-yl)-L-phenylalanine
methyl ester is provided in working examples.) The latter compound can be
reacted with hydrogen chloride to give the hydrochloride salt of a 4'-
(heterocyclyl)phenylalanine methyl ester, which would be suitable for use in a
30 reaction described above.

Alternatively for example, N-*tert*-butoxycarbonyl-4'-
iodophenylalanine methyl ester can be converted in one step to give either N-
tert-butoxycarbonyl-4'-(trimethylstannyl)phenylalanine methyl ester (*see.*,

5 *Syn. Lett.* **1997**, (7), 1403-1405) or N-*tert*-butoxycarbonyl-4'-
(pinacolatoborono)phenylalanine methyl ester (*see.*, *Tet. Lett.* **1999**, 40(2),
213-216). Either of the latter compounds could be reacted with a suitably
substituted iodoheterocycle or bromoheterocycle, utilizing a palladium
catalyst to form a carbon-carbon bond, to give an N-*tert*-butoxycarbonyl-4'-
10 (heterocyclyl)phenylalanine methyl ester (*see.*, *Syn. Lett.* **1997**, (7), 1403-
1405; *Tetrahedron Lett.* **1999**, 40(2), 213-216). The *tert*-butoxycarbonyl
group of the latter compound could be removed as described above.
Alternatively for example, N-*tert*-butoxycarbonyl-4'-iodophenylalanine
methyl ester could be reacted with a suitably substituted heterocycle featuring
15 an N-H group, utilizing a copper catalyst to form a carbon-nitrogen bond, to
give an N-*tert*-butoxycarbonyl-4'-(heterocyclyl)phenylalanine methyl ester
(*see.*, *J. Med. Chem.* **1998**, 41(13), 2268-2277). The *tert*-butoxycarbonyl
group of the latter compound could be removed as described above.
Alternatively, for example, commercially available 4'-nitrophenylalanine
20 (Aldrich) could be converted in three steps to N-*tert*-butoxycarbonyl-4'-
aminophenylalanine methyl ester (*see.*, *J. Org. Chem.* **1999**, 64(10), 3467-
3475). The latter compound could be reacted with an omega-haloalkyl-
isocyanate to give an N-*tert*-butoxycarbonyl-4'-(omega-
haloalkylaminocarbonyl)-amino)-phenylalanine methyl ester (*see.*, *Khim.*
25 *Farm. Zh.* **1984**, 18(12), 1432-1436). The latter compound could be reacted
with sodium hydride to give an N-*tert*-butoxycarbonyl-4'-(1,3-diaza-2-
oxoalicyclyl)phenylalanine methyl ester (*see.*, *Bioorg. Med. Chem. Lett.*
1999, 9(5), 749-754). The *tert*-butoxycarbonyl group of the latter compound
could be removed as described above.

30
For example, amino acid derivatives (a) or (b) where Ar¹ is
heteroaryl, these can be prepared by methods well known in the art. For
example, the procedures of Schow et al. (*J. Org. Chem.* **1994**, 59(22), 6850-
6852) or the procedures of Ye et al. (*J. Org. Chem.* **1995**, 60(8), 2640-2641)

5 or the procedures of Myers et al. (*J. Org. Chem.* **1996**, 61(22), 813-815) may
be used to prepare 5-hydroxypyridin-2-ylalanine. Using standard procedures,
the carboxyl group could be protected with a methyl ester, and the amino
group could be protected with *tert*-butoxycarbonyl group. The procedure of
Ksander et al. (*J. Med. Chem.* **1995**, 38(10), 1689-1700) could be used to
10 convert the phenol of such a protected derivative into a triflate. The
procedure of Firooznia et al. (*Tet. Lett.* **1999**, 40(2), 213-216) could be used
to convert the triflate into pinacolatoborono derivative. As described above,
the pinacolatoborono derivative could be applied in a palladium catalyzed
coupling with a suitably substituted iodoheterocycle or bromoheterocycle.

15 The procedures of Yamano et al. (*Tetrahedron.* **1992**, 48(8), 1457-
1464) or the procedures of Andrews et al. (*J. Chem. Soc. Perkin Trans. 1.*
1995, 11, 1335-1340) may be used to prepare 2-hydroxypyridin-2-ylalanine.
Using procedures described above, this could be converted into a protected
20 pinacolatoborono derivative, which could be applied in a palladium catalyzed
coupling with a suitably substituted iodoheterocycle or bromoheterocycle.

25 The procedures of Shiotani et al. (*J. Org. Chem.* **1997**, 34(3), 941-
952) could be used to prepare a pyridin-2-one fused via the 4 and 5 positions
with a tetrahydrofuran. Following methods described in the working
examples, this compound could be elaborated into a 1-methyl-3-iodopyridin-
2-one fused via the 4 and 5 positions with a tetrahydrofuran. As described
above, this compound could be applied in a palladium catalyzed coupling with
a suitably protected pinacolatoborono phenylalanine or a suitably protected
30 pinacolatoborono heteroarylalanine.

The procedures of Adembri (*J. Chem. Soc. Perkin Trans. 1.* **1975**,
2190-2194) could be used to prepare a pyridin-2-one fused via the 4 and 5
positions with an isoxazole. Following methods described in the working

5 examples, this compound could be elaborated into a 1-methyl-3-iodopyridin-
2-one fused via the 4 and 5 positions with an isoxazole. As described above,
this compound could be applied in a palladium catalyzed coupling with a
suitably protected pinacolatoborono phenylalanine or a suitably protected
pinacolatoborono heteroarylalanine.

10 The procedures of Dorofeenko et al. (*Khim. Geterotsikl. Soedin.*
1976, 533) could be used to prepare a pyridin-2-one fused via the 4 and 5
positions with a furan. Following methods described in the working
examples, this compound could be elaborated into a 1-methyl-3-iodopyridin-
15 2-one fused via the 4 and 5 positions with an isoxazole. As described above,
this compound could be applied in a palladium catalyzed coupling with a
suitably protected pinacolatoborono phenylalanine or a suitably protected
pinacolato heteroarylalanine.

20 The sulfonyl chlorides employed in the above reaction are also either
known compounds or compounds that can be prepared from known
compounds by conventional synthetic procedures. Such compounds are
typically prepared from the corresponding sulfonic acid, i.e., from
compounds of the formula R^5-SO_3H where R^5 is as defined above, using
25 phosphorous trichloride and phosphorous pentachloride. This reaction is
generally conducted by contacting the sulfonic acid with about 2 to 5 molar
equivalents of phosphorous trichloride and phosphorous pentachloride, either
neat or in an inert solvent, such as dichloromethane, at temperature in the
range of about 0°C to about 80°C for about 1 to about 48 hours to afford the
30 sulfonyl chloride. Alternatively, the sulfonyl chloride can be prepared from
the corresponding thiol compound, i.e., from compounds of the formula R^5-SH
where R^5 is as defined herein, by treating the thiol with chlorine (Cl_2) and
water under conventional reaction conditions.


5 Examples of sulfonyl chlorides suitable for use in this invention
include, but are not limited to, methanesulfonyl chloride, 2-propanesulfonyl
chloride, 1-butanesulfonyl chloride, benzenesulfonyl chloride, 1-
naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, *p*-
toluenesulfonyl chloride, α -toluenesulfonyl chloride, 4-
10 acetamidobenzenesulfonyl chloride, 4-amidinobenzenesulfonyl chloride, 4-
tert-butylbenzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, 2-
carboxybenzenesulfonyl chloride, 4-cyanobenzenesulfonyl chloride, 3,4-
dichlorobenzenesulfonyl chloride, 3,5-dichlorobenzenesulfonyl chloride, 3,4-
dimethoxybenzenesulfonyl chloride, 3,5-ditrifluoromethylbenzenesulfonyl
15 chloride, 4-fluorobenzenesulfonyl chloride, 4-methoxybenzenesulfonyl
chloride, 2-methoxycarbonylbenzenesulfonyl chloride, 4-
methylamidobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, 4-
thioamidobenzenesulfonyl chloride, 4-trifluoromethylbenzenesulfonyl
chloride, 4-trifluoromethoxybenzenesulfonyl chloride, 2,4,6-
20 trimethylbenzenesulfonyl chloride, 2-phenylethanesulfonyl chloride, 2-
thiophenesulfonyl chloride, 5-chloro-2-thiophenesulfonyl chloride, 2,5-
dichloro-4-thiophenesulfonyl chloride, 2-thiazolesulfonyl chloride, 2-methyl-
4-thiazolesulfonyl chloride, 1-methyl-4-imidazolesulfonyl chloride, 1-methyl-
4-pyrazolesulfonyl chloride, 5-chloro-1,3-dimethyl-4-pyrazolesulfonyl
25 chloride, 3-pyridinesulfonyl chloride, 2-pyrimidinesulfonyl chloride and the
like. If desired, a sulfonyl fluoride, sulfonyl bromide or sulfonic acid
anhydride may be used in place of the sulfonyl chloride in the above reaction
to form the sulfonamide intermediate **5**.

30 If desired, sulfonamide intermediate **5** can be alkylated at the
sulfonamide nitrogen atom to provide compound **6**. For example, **5** can be
contacted with excess diazomethane (generated, for example, using 1-methyl-
3-nitro-1-nitrosoguanidine and sodium hydroxide) to afford **6** where R⁶ is

5 methyl. Other conventional alkylation procedures and reagents may also be employed to prepare various compounds of this invention.

In another preferred embodiment, compounds of this invention (Ia) may be prepared by displacement of a leaving group as shown in Scheme 2:

Scheme 2




10 where B, Ar¹, Ar², and X are as defined herein; A' is heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic containing two nitrogen atoms in the heteroaryl or heterocyclic ring; and L¹ is a leaving group, such as chloro, bromo, iodo, sulfonate ester and the like.

15 Typically, this reaction is conducted by combining approximately stoichiometric equivalents of 7 and 8 in a suitable inert diluent such as water, dimethylsulfoxide (DMSO) and the like, with an excess of a suitable base such as sodium bicarbonate, sodium hydroxide, etc. to scavenge the acid
20 generated by the reaction. The reaction is preferably conducted at from about 25°C to about 100°C until reaction completion which typically occurs within 1 to about 24 hours. This reaction is further described in U.S. Patent No. 3,598,859, which is incorporated herein by reference in its entirety. Upon
25 reaction completion, the product 9 is recovered by conventional methods including precipitation, chromatography, filtration and the like.

5 In still another alternative embodiment, compounds of this invention can be prepared by reductive amination of a suitable 2-oxocarboxylic acid ester, **10**, such as a pyruvate ester, as shown in Scheme 3:

Scheme 3



where B, Ar¹, Ar², and X are as defined herein.


10 Generally, this reaction is conducted by combining equimolar amounts of **10** and **11** in an inert diluent such as methanol, ethanol and the like under conditions which provide for imine formation (not shown). The imine formed is then reduced under conventional conditions by a suitable reducing agent such as sodium cyanoborohydride, H₂/palladium on carbon and the like to form the product **12**. In a particularly preferred embodiment,

15 the reducing agent is H₂/palladium on carbon which is incorporated into the initial reaction medium thereby permitting imine reduction *in situ* in a one pot procedure to provide **12**. The reaction is preferably conducted at from about 20°C to about 80°C at a pressure of from 1 to 10 atmospheres until reaction

20 completion which typically occurs within 1 to about 24 hours. Upon reaction completion, the product **12** is recovered by conventional methods including chromatography, filtration and the like.

25 Alternatively, certain compounds of this invention can be prepared via a rhodium-catalyzed insertion reaction as shown in Scheme 4:


Scheme 4



where A'' is heteroaryl or substituted heteroaryl containing two nitrogen atoms in the heteroaryl ring, and B, Ar¹, Ar², and X (preferably alkoxy) are as defined herein. Typically, this reaction is conducted using rhodium acetate dimer, Rh₂(OAc)₄, in an inert diluent such as toluene at a temperature ranging from about 25°C to about 80°C for about 1 to 12 hours to afford 15. This reaction is described further in B. R. Henke et. al., *J. Med. Chem.* **1998**, *41*, 5020-5036 and references cited therein.

Similarly, certain compounds of this invention can be prepared by the copper-catalyzed coupling reaction shown in Scheme 5:

Scheme 5



where A'' is as defined herein, X³ is halogen, such as chloro, bromo or iodo (preferably iodo) and B, Ar¹, Ar², and X (preferably alkoxy) are as defined

5 herein. Typically, this reaction is conducted using copper iodide (CuI) and
potassium carbonate in an inert diluent such as *N,N*-dimethyl acetamide
(DMA) at a temperature ranging from about 60°C to about 120°C for about
12 to 36 hours to afford **15**. This reaction is described further in D. Ma et.
al., *J. Am. Chem. Soc.* **1998**, *120*, 12459-12467 and references cited therein.
10 It should be recognized by one skilled in the art that although Applicants
have depicted use of amino acid of formula (a) in the above schemes that one
could readily use amino acid of formula (b) in the above reactions to get to
compound of Formula (Ib).

15 For ease of synthesis, the compounds of this invention are typically
prepared as an ester, i.e., where X is an alkoxy or substituted alkoxy group
and the like. If desired, the ester group can be hydrolysed using conventional
conditions and reagents to provide the corresponding carboxylic acid.
Typically, this reaction is conducted by treating the ester with at least one
20 equivalent of an alkali metal hydroxide, such as lithium, sodium or potassium
hydroxide, in an inert diluent, such as methanol or mixtures of methanol and
water, at a temperature ranging about 0°C to about 24°C for about 1 to about
12 hours. Alternatively, benzyl esters may be removed by hydrogenolysis
using a palladium catalyst, such as palladium on carbon, and *tert*-butyl esters
25 can be removed using formic acid to afford the corresponding carboxylic
acid.

30 As will be apparent to those skilled in the art, other functional groups
present on any of the substituents of the compounds of formulas I-II can be
readily modified or derivatized either before or after the above-described
synthetic reactions using well-known synthetic procedures. For example, a
nitro group present on a substituent of a compound of formula I-II or an
intermediate thereof may be readily reduced by hydrogenation in the presence
of a palladium catalyst, such as palladium on carbon, to provide the

5 corresponding amino group. This reaction is typically conducted at a
temperature of from about 20°C to about 50°C for about 6 to about 24 hours
in an inert diluent, such as methanol. Compounds having a nitro group on
the Ar² substituent can be prepared, for example, by using a 4-
nitrophenylalanine derivative and the like in the above-described coupling
10 reactions.

Similarly, a pyridyl group can be hydrogenated in the presence of a
platinum catalyst, such as platinum oxide, in an acidic diluent to provide the
corresponding piperidinyl analogue. Generally, this reaction is conducted by
15 treating the pyridine compound with hydrogen at a pressure ranging from
about 20 psi to about 60 psi, preferably about 40 psi, in the presence of the
catalyst at a temperature of about 20°C to about 50°C for about 2 to about 24
hours in an acidic diluent, such as a mixture of methanol and aqueous
hydrochloric acid.

20 Additionally, when the Ar¹ substituent of a compound of formula I-II
contains a primary or secondary amino group, such amino groups can be
further derivatized either before or after the above coupling reactions to
provide, by way of example, amides, sulfonamides, ureas, thioureas,
25 carbamates, secondary or tertiary amines and the like. Compounds having a
primary amino group on the Ar¹ substituent may be prepared, for example, by
reduction of the corresponding nitro compound as described above.

30 By way of illustration, a compound of formula I-II or an intermediate
thereof having a substituent containing a primary or secondary amino group,
can be readily *N*-acylated using conventional acylating reagents and
conditions to provide the corresponding amide. This acylation reaction is
typically conducted by treating the amino compound with at least one
equivalent, preferably about 1.1 to about 1.2 equivalents, of a carboxylic acid

5 in the presence of a coupling reagent such as a carbodiimide, BOP reagent
(benzotriazol-1-yloxy-tris(dimethylamino)phosphonium
hexafluorophosphonate) and the like, in an inert diluent, such as
dichloromethane, chloroform, acetonitrile, tetrahydrofuran, *N,N*-
dimethylformamide and the like, at a temperature ranging from about 0°C to
10 about 37°C for about 4 to about 24 hours. Preferably, a promoter, such as
N-hydroxysuccinimide, 1-hydroxy-benzotriazole and the like, is used to
facilitate the acylation reaction. Examples of carboxylic acids suitable for use
in this reaction include, but are not limited to, *N-tert*-
butyloxycarbonylglycine, *N-tert*-butyloxycarbonyl-L-phenylalanine, *N-tert*-
15 butyloxycarbonyl-L-aspartic acid benzyl ester, benzoic acid, *N-tert*-
butyloxycarbonylisonipecotic acid, *N*-methylisonipecotic acid, *N-tert*-
butyloxycarbonylnipecotic acid, *N-tert*-butyloxycarbonyl-L-
tetrahydroisoquinoline-3-carboxylic acid, *N*-(toluene-4-sulfonyl)-L-proline
and the like.

20 Alternatively, a compound of formula I-II or an intermediate thereof
containing a primary or secondary amino group can be *N*-acylated using an
acyl halide or a carboxylic acid anhydride to form the corresponding amide.
This reaction is typically conducted by contacting the amino compound with
25 at least one equivalent, preferably about 1.1 to about 1.2 equivalents, of the
acyl halide or carboxylic acid anhydride in an inert diluent, such as
dichloromethane, at a temperature ranging from about -70°C to about 40°C
for about 1 to about 24 hours. If desired, an acylation catalyst such as 4-
(*N,N*-dimethylamino)pyridine may be used to promote the acylation reaction.
30 The acylation reaction is preferably conducted in the presence of a suitable
base to scavenge the acid generated during the reaction. Suitable bases
include, by way of example, tertiary amines, such as triethylamine,
diisopropylethylamine, *N*-methylmorpholine and the like. Alternatively, the

5 reaction can be conducted under Schotten-Baumann-type conditions using aqueous alkali, such as sodium hydroxide and the like.

10 Examples of acyl halides and carboxylic acid anhydrides suitable for use in this reaction include, but are not limited to, 2-methylpropionyl chloride, trimethylacetyl chloride, phenylacetyl chloride, benzoyl chloride, 2-bromobenzoyl chloride, 2-methylbenzoyl chloride, 2-trifluoro-methylbenzoyl chloride, isonicotinoyl chloride, nicotinoyl chloride, picolinoyl chloride, acetic anhydride, succinic anhydride, and the like. Carbamyl chlorides, such as *N,N*-dimethylcarbamyl chloride, *N,N*-diethylcarbamyl chloride and the like, can also be used in this reaction to provide ureas. Similarly, dicarbonates, such as di-*tert*-butyl dicarbonate, may be employed to provide carbamates.

15 In a similar manner, a compound of formula I-II or an intermediate thereof containing a primary or secondary amino group may be *N*-sulfonated to form a sulfonamide using a sulfonyl halide or a sulfonic acid anhydride. Sulfonyl halides and sulfonic acid anhydrides suitable for use in this reaction include, but are not limited to, methanesulfonyl chloride, chloromethanesulfonyl chloride, *p*-toluenesulfonyl chloride, 20 trifluoromethanesulfonic anhydride, and the like. Similarly, sulfamoyl chlorides, such as dimethylsulfamoyl chloride, can be used to provide sulfamides (e.g., >N-SO₂-N<).

25 Additionally, a primary and secondary amino group present on a substituent of a compound of formula I-II or an intermediate thereof can be reacted with an isocyanate or a thioisocyanate to give a urea or thiourea, respectively. This reaction is typically conducted by contacting the amino compound with at least one equivalent, preferably about 1.1 to about 1.2 equivalents, of the isocyanate or thioisocyanate in an inert diluent, such as

30

5 toluene and the like, at a temperature ranging from about 24°C to about 37°C
for about 12 to about 24 hours. The isocyanates and thioisocyanates used in
this reaction are commercially available or can be prepared from
commercially available compounds using well-known synthetic procedures.
For example, isocyanates and thioisocyanates are readily prepared by reacting
10 the appropriate amine with phosgene or thiophosgene. Examples of
isocyanates and thioisocyanates suitable for use in this reaction include, but
are not limited to, ethyl isocyanate, *n*-propyl isocyanate, 4-cyanophenyl
isocyanate, 3-methoxyphenyl isocyanate, 2-phenylethyl isocyanate, methyl
thioisocyanate, ethyl thioisocyanate, 2-phenylethyl thioisocyanate, 3-
15 phenylpropyl thioisocyanate, 3-(*N,N*-diethylamino)propyl thioisocyanate,
phenyl thioisocyanate, benzyl thioisocyanate, 3-pyridyl thioisocyanate,
fluorescein isothiocyanate (isomer I) and the like.

20 Furthermore, when a compound of formula I-II or an intermediate
thereof contains a primary or secondary amino group, the amino group can be
reductively alkylated using aldehydes or ketones to form a secondary or
tertiary amino group. This reaction is typically conducted by contacting the
amino compound with at least one equivalent, preferably about 1.1 to about
1.5 equivalents, of an aldehyde or ketone and at least one equivalent based on
25 the amino compound of a metal hydride reducing agent, such as sodium
cyanoborohydride, in an inert diluent, such as methanol, tetrahydrofuran,
mixtures thereof and the like, at a temperature ranging from about 0°C to
about 50°C for about 1 to about 72 hours. Aldehydes and ketones suitable
for use in this reaction include, by way of example, benzaldehyde, 4-
30 chlorobenzaldehyde, valeraldehyde and the like.

 In a similar manner, when a compound of formula I-II or an
intermediate thereof has a substituent containing a hydroxyl group, the
hydroxyl group can be further modified or derivatized either before or after

5 the above coupling reactions to provide, by way of example, ethers, carbamates and the like.

10 By way of example, a compound of formula I-II or an intermediate thereof having a substituent containing a hydroxyl group, such as where the lactam ring is 4-hydroxypyridone group, can be readily *O*-alkylated to form ethers. This *O*-alkylation reaction is typically conducted by contacting the hydroxy compound with a suitable alkali or alkaline earth metal base, such as potassium carbonate, in an inert diluent, such as acetone, 2-butanone and the like, to form the alkali or alkaline earth metal salt of the hydroxyl group.

15 This salt is generally not isolated, but is reacted *in situ* with at least one equivalent of an alkyl or substituted alkyl halide or sulfonate, such as an alkyl chloride, bromide, iodide, mesylate or tosylate, to afford the ether.

20 Generally, this reaction is conducted at a temperature ranging from about 60°C to about 150°C for about 24 to about 72 hours. Preferably, a catalytic amount of sodium or potassium iodide is added to the reaction mixture when an alkyl chloride or bromide is employed in the reaction.

25 Examples of alkyl or substituted alkyl halides and sulfonates suitable for use in this reaction include, but are not limited to, *tert*-butyl bromoacetate, *N-tert*-butyl chloroacetamide, 1-bromoethylbenzene, ethyl α -bromophenylacetate, 2-(*N*-ethyl-*N*-phenylamino)ethyl chloride, 2-(*N,N*-ethylamino)ethyl chloride, 2-(*N,N*-diisopropylamino)ethyl chloride, 2-(*N,N*-dibenzylamino)ethyl chloride, 3-(*N,N*-ethylamino)propyl chloride, 3-(*N*-benzyl-*N*-methylamino)propyl chloride, *N*-(2-chloroethyl)morpholine, 2-

30 (hexamethyleneimino)ethyl chloride, 3-(*N*-methylpiperazine)propyl chloride, 1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine, 2-(4-hydroxy-4-phenylpiperidine)ethyl chloride, *N-tert*-butyloxycarbonyl-3-piperidinemethyl tosylate, and the like.

5 Alternatively, a hydroxyl group present on a substituent of a
compound of formula I-II or an intermediate thereof can be *O*-alkylating using
the Mitsunobu reaction. In this reaction, an alcohol, such as 3-(*N,N*-
dimethylamino)-1-propanol and the like, is reacted with about 1.0 to about
1.3 equivalents of triphenylphosphine and about 1.0 to about 1.3 equivalents
10 of diethyl azodicarboxylate in an inert diluent, such as tetrahydrofuran, at a
temperature ranging from about -10°C to about 5°C for about 0.25 to about 1
hour. About 1.0 to about 1.3 equivalents of a hydroxy compound, such as *N*-
tert-butyltyrosine methyl ester, is then added and the reaction mixture is
stirred at a temperature of about 0°C to about 30°C for about 2 to about 48
15 hours to provide the *O*-alkylated product.

 In a similar manner, a compound of formula I-II or an intermediate
thereof containing an aryl hydroxy group can be reacted with an aryl iodide to
provide a diaryl ether. Generally, this reaction is conducted by forming the
alkali metal salt of the hydroxyl group using a suitable base, such as sodium
20 hydride, in an inert diluent such as xylenes at a temperature of about -25°C to
about 10°C. The salt is then treated with about 1.1 to about 1.5 equivalents
of cuprous bromide dimethyl sulfide complex at a temperature ranging from
about 10°C to about 30°C for about 0.5 to about 2.0 hours, followed by
25 about 1.1 to about 1.5 equivalents of an aryl iodide, such as sodium 2-
iodobenzoate and the like. The reaction is then heated to about 70°C to about
150°C for about 2 to about 24 hours to provide the diaryl ether.

 Additionally, a hydroxy-containing compound can also be readily
30 derivatized to form a carbamate. In one method for preparing such
carbamates, a hydroxy compound of formula I-II or an intermediate thereof is
contacted with about 1.0 to about 1.2 equivalents of 4-nitrophenyl
chloroformate in an inert diluent, such as dichloromethane, at a temperature
ranging from about -25°C to about 0°C for about 0.5 to about 2.0 hours.

5 Treatment of the resulting carbonate with an excess, preferably about 2 to
about 5 equivalents, of a trialkylamine, such as triethylamine, for about 0.5 to
2 hours, followed by about 1.0 to about 1.5 equivalents of a primary or
secondary amine provides the carbamate. Examples of amines suitable for
10 using in this reaction include, but are not limited to, piperazine, 1-
methyldpiperazine, 1-acetyldpiperazine, morpholine, thiomorpholine,
pyrrolidine, piperidine and the like.

15 Alternatively, in another method for preparing carbamates, a hydroxy-
containing compound is contacted with about 1.0 to about 1.5 equivalents of a
carbonyl chloride in an inert diluent, such as dichloromethane, at a
temperature ranging from about 25°C to about 70°C for about 2 to about 72
hours. Typically, this reaction is conducted in the presence of a suitable base
to scavenge the acid generated during the reaction. Suitable bases include, by
way of example, tertiary amines, such as triethylamine,
20 diisopropylethylamine, *N*-methyldmorpholine and the like. Additionally, at
least one equivalent (based on the hydroxy compound) of 4-(*N,N*-
dimethylamino)pyridine is preferably added to the reaction mixture to
facilitate the reaction. Examples of carbonyl chlorides suitable for use in this
reaction include, by way of example, dimethylcarbonyl chloride,
25 diethylcarbonyl chloride and the like.

30 Likewise, when a compound of formula I-II or an intermediate thereof
contains a primary or secondary hydroxyl group, such hydroxyl groups can
be readily converted into a leaving group and displaced to form, for example,
amines, sulfides and fluorides. Generally, when a chiral compound is
employed in these reactions, the stereochemistry at the carbon atom attached
to the derivatized hydroxyl group is typically inverted.

5 These reactions are typically conducted by first converting the
hydroxyl group into a leaving group, such as a tosylate, by treatment of the
hydroxy compound with at least one equivalent of a sulfonyl halide, such as
p-toluenesulfonyl chloride and the like, in pyridine. This reaction is
generally conducted at a temperature of from about 0°C to about 70°C for
10 about 1 to about 48 hours. The resulting tosylate can then be readily
displaced with sodium azide, for example, by contacting the tosylate with at
least one equivalent of sodium azide in an inert diluent, such as a mixture of
N,N-dimethylformamide and water, at a temperature ranging from about 0°C
to about 37°C for about 1 to about 12 hours to provide the corresponding
15 azido compound. The azido group can then be reduced by, for example,
hydrogenation using a palladium on carbon catalyst to provide the amino
(-NH₂) compound.

 Similarly, a tosylate group can be readily displaced by a thiol to form
20 a sulfide. This reaction is typically conducted by contacting the tosylate with
at least one equivalent of a thiol, such as thiophenol, in the presence of a
suitable base, such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), in an inert
diluent, such as *N,N*-dimethylformamide, at a temperature of from about 0°C
to about 37°C for about 1 to about 12 hours to provide the sulfide.

25 Additionally, treatment of a tosylate with morpholinosulfur trifluoride in an
inert diluent, such as dichloromethane, at a temperature ranging from about
0°C to about 37°C for about 12 to about 24 hours affords the corresponding
fluoro compound.

30 Furthermore, a compound of formula I-II or an intermediate thereof
having a substituent containing an iodoaryl group can be readily converted
either before or after the above coupling reactions into a biaryl compound.
Typically, this reaction is conducted by treating the iodoaryl compound with
about 1.1 to about 2 equivalents of an arylzinc iodide, such as 2-

5 (methoxycarbonyl)phenylzinc iodide, in the presence of a palladium catalyst,
such as palladium tetra(triphenylphosphine), in an inert diluent, such as
tetrahydrofuran, at a temperature ranging from about 24°C to about 30°C
until reaction completion. This reaction is further described, for example, in
Rieke, *J. Org. Chem.* **1991**, 56, 1445. Additional methods for preparing
10 biaryl derivatives are disclosed in International Publication Number WO
98/53817, published December 3, 1998, the disclosure of which is
incorporated herein by reference in its entirety.

15 In some cases, the compounds of formula I-II or intermediates thereof
may contain substituents having one or more sulfur atoms. When present,
such sulfur atoms can be oxidized either before or after the above coupling
reactions to provide a sulfoxide or sulfone compound using conventional
reagents and reaction conditions. Suitable reagents for oxidizing a sulfide
compound to a sulfoxide include, by way of example, hydrogen peroxide, 3-
20 chloroperoxybenzoic acid (MCPBA), sodium periodate and the like. The
oxidation reaction is typically conducted by contacting the sulfide compound
with about 0.95 to about 1.1 equivalents of the oxidizing reagent in an inert
diluent, such as dichloromethane, at a temperature ranging from about -50°C
to about 75°C for about 1 to about 24 hours. The resulting sulfoxide can then
25 be further oxidized to the corresponding sulfone by contacting the sulfoxide
with at least one additional equivalent of an oxidizing reagent, such as
hydrogen peroxide, MCPBA, potassium permanganate and the like.
Alternatively, the sulfone can be prepared directly by contacting the sulfide
with at least two equivalents, and preferably an excess, of the oxidizing
30 reagent. Such reactions are described further in March, "*Advanced Organic
Chemistry*", 4th Ed., pp. 1201-1202, Wiley Publisher, 1992.

Other procedures and reaction conditions for preparing the compounds
of this invention are described in the examples set forth below. Additionally,

5 other procedures for preparing compounds useful in certain aspects of this
invention are disclosed in U.S. Applications Serial Nos. 09/489,377 and
09/489,378, filed on January 21, 2000, entitled "Compounds Which Inhibit
Leucocyte Adhesion Mediated by VLA-4" (Attorney Docket Nos. 002010-
517 and 002010-525); the disclosure of which is incorporated herein by
10 reference in its entirety.

Pharmaceutical Formulations

15 When employed as pharmaceuticals, the compounds of this invention
are usually administered in the form of pharmaceutical compositions. These
compounds can be administered by a variety of routes including oral, rectal,
transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These
compounds are effective as both injectable and oral compositions. Such
compositions are prepared in a manner well known in the pharmaceutical art
and comprise at least one active compound.

20 This invention also includes pharmaceutical compositions which
contain, as the active ingredient, one or more of the compounds of formula I-
VII above associated with pharmaceutically acceptable carriers. In making
the compositions of this invention, the active ingredient is usually mixed with
25 an excipient, diluted by an excipient or enclosed within such a carrier which
can be in the form of a capsule, sachet, paper or other container. The
excipient employed is typically an excipient suitable for administration to
human subjects or other mammals. When the excipient serves as a diluent, it
can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier
30 or medium for the active ingredient. Thus, the compositions can be in the
form of tablets, pills, powders, lozenges, sachets, cachets, elixirs,
suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid
medium), ointments containing, for example, up to 10% by weight of the

5 active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

10 In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

15 Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

25 The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

5 The active compound is effective over a wide dosage range and is
generally administered in a pharmaceutically effective amount. It, will be
understood, however, that the amount of the compound actually administered
will be determined by a physician, in the light of the relevant circumstances,
including the condition to be treated, the chosen route of administration, the
10 actual compound administered, the age, weight, and response of the
individual patient, the severity of the patient's symptoms, and the like.

 For preparing solid compositions such as tablets, the principal active
ingredient is mixed with a pharmaceutical excipient to form a solid
15 preformulation composition containing a homogeneous mixture of a
compound of the present invention. When referring to these preformulation
compositions as homogeneous, it is meant that the active ingredient is
dispersed evenly throughout the composition so that the composition may be
readily subdivided into equally effective unit dosage forms such as tablets,
20 pills and capsules. This solid preformulation is then subdivided into unit
dosage forms of the type described above containing from, for example, 0.1
to about 500 mg of the active ingredient of the present invention.

 The tablets or pills of the present invention may be coated or
25 otherwise compounded to provide a dosage form affording the advantage of
prolonged action. For example, the tablet or pill can comprise an inner
dosage and an outer dosage component, the latter being in the form of an
envelope over the former. The two components can be separated by an
enteric layer which serves to resist disintegration in the stomach and permit
30 the inner component to pass intact into the duodenum or to be delayed in
release. A variety of materials can be used for such enteric layers or
coatings, such materials including a number of polymeric acids and mixtures
of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose
acetate.

09910702 1072001

5 The liquid forms in which the novel compositions of the present
invention may be incorporated for administration orally or by injection
include aqueous solutions suitably flavored syrups, aqueous or oil
suspensions, and flavored emulsions with edible oils such as cottonseed oil,
sesame oil, coconut oil, or peanut oil, as well as elixirs and similar
10 pharmaceutical vehicles.

15 Compositions for inhalation or insufflation include solutions and
suspensions in pharmaceutically acceptable, aqueous or organic solvents, or
mixtures thereof, and powders. The liquid or solid compositions may contain
suitable pharmaceutically acceptable excipients as described *supra*.
Preferably the compositions are administered by the oral or nasal respiratory
route for local or systemic effect. Compositions in preferably
pharmaceutically acceptable solvents may be nebulized by use of inert gases.
Nebulized solutions may be breathed directly from the nebulizing device or
20 the nebulizing device may be attached to a face masks tent, or intermittent
positive pressure breathing machine. Solution, suspension, or powder
compositions may be administered, preferably orally or nasally, from devices
which deliver the formulation in an appropriate manner.

25 The following formulation examples illustrate the pharmaceutical
compositions of the present invention.

Formulation Example 1

30 Hard gelatin capsules containing the following ingredients are
prepared:

<u>Ingredient</u>	<u>Quantity</u> <u>(mg/capsule)</u>
Active Ingredient	30.0
Starch	305.0
Magnesium stearate	5.0

5 The above ingredients are mixed and filled into hard gelatin capsules
in 340 mg quantities.

Formulation Example 2

A tablet formula is prepared using the ingredients below:

10

<u>Ingredient</u>	<u>Quantity</u> <u>(mg/tablet)</u>
Active Ingredient	25.0
Cellulose, microcrystalline	200.0
15 Colloidal silicon dioxide	10.0
Stearic acid	5.0

The components are blended and compressed to form tablets, each
weighing 240 mg.

20

Formulation Example 3

A dry powder inhaler formulation is prepared containing the following
components:

25

<u>Ingredient</u>	<u>Weight %</u>
Active Ingredient	5
Lactose	95

30 The active mixture is mixed with the lactose and the mixture is added
to a dry powder inhaling appliance.

Formulation Example 4

35 Tablets, each containing 30 mg of active ingredient, are prepared as
follows:

09910702.072001

5		Quantity
	<u>Ingredient</u>	<u>(mg/tablet)</u>
	Active Ingredient	30.0 mg
	Starch	45.0 mg
10	Microcrystalline cellulose	35.0 mg
	Polyvinylpyrrolidone	
	(as 10% solution in water)	4.0 mg
	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
15	Talc	<u>1.0 mg</u>
	Total	120 mg

09910702 " 072001

The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50° to 60°C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation Example 5

Capsules, each containing 40 mg of medicament are made as follows:

30		Quantity
	<u>Ingredient</u>	<u>(mg/capsule)</u>
	Active Ingredient	40.0 mg
	Starch	109.0 mg
	Magnesium stearate	<u>1.0 mg</u>
35	Total	150.0 mg

The active ingredient, cellulose, starch, an magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.

5

Formulation Example 6

Suppositories, each containing 25 mg of active ingredient are made as follows:

10

<u>Ingredient</u>	<u>Amount</u>
Active Ingredient	25 mg
Saturated fatty acid glycerides to	2,000 mg

15

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.

20

Formulation Example 7

Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

25

<u>Ingredient</u>	<u>Amount</u>
Active Ingredient	50.0 mg
Xanthan gum	4.0 mg
Sodium carboxymethyl cellulose (11%)	
Microcrystalline cellulose (89%)	50.0 mg
Sucrose	1.75 g
Sodium benzoate	10.0 mg
Flavor and Color	q.v.
Purified water to	5.0 ml

35

The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

40

Formulation Example 8

<u>Ingredient</u>	<u>Quantity (mg/capsule)</u>
Active Ingredient	15.0 mg
Starch	407.0 mg
Magnesium stearate	<u>3.0 mg</u>
Total	425.0 mg

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 560 mg quantities.

Formulation Example 9

An intravenous formulation may be prepared as follows:

<u>Ingredient</u>	<u>Quantity</u>
Active Ingredient	250.0 mg
Isotonic saline	1000 ml

Formulation Example 10

A topical formulation may be prepared as follows:

<u>Ingredient</u>	<u>Quantity</u>
Active Ingredient	1-10 g
Emulsifying Wax	30 g
Liquid Paraffin	20 g
White Soft Paraffin	to 100 g

The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.

5 Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of
10 pharmaceutical agents is well known in the art. See, e.g., U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

15 Direct or indirect placement techniques may be used when it is desirable or necessary to introduce the pharmaceutical composition to the brain. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system used for the transport of biological factors to
20 specific anatomical regions of the body is described in U.S. Patent 5,011,472 which is herein incorporated by reference.

Indirect techniques, which are generally preferred, usually involve
25 formulating the compositions to provide for drug latention by the conversion of hydrophilic drugs into lipid-soluble drugs. Latention is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by
30 intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.

0910702-072001

5

10

20

30

5 as T cells, B cells, monocytes, eosinophils, and basophils. A number of leukocyte cell lines can also be used, examples include Jurkat and U937.

10 The test compounds can also be tested for the ability to competitively inhibit binding between VLA-4 and VCAM-1, or between VLA-4 and a labeled compound known to bind VLA-4 such as a compound of this invention or antibodies to VLA-4. In these assays, the VCAM-1 can be immobilized on a solid surface. VCAM-1 may also be expressed as a recombinant fusion protein having an Ig tail (e.g., IgG) so that binding to VLA-4 may be detected in an immunoassay. Alternatively, VCAM-1
15 expressing cells, such as activated endothelial cells or VCAM-1 transfected fibroblasts can be used. For assays to measure the ability to block adhesion to brain endothelial cells, the assays described in International Patent Application Publication No. WO 91/05038 are particularly preferred. This application is incorporated herein by reference in its entirety.

20 Many assay formats employ labelled assay components. The labelling systems can be in a variety of forms. The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. A wide variety of labels may be used. The component may
25 be labelled by any one of several methods. The most common method of detection is the use of autoradiography with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P labelled compounds or the like. Non-radioactive labels include ligands which bind to labelled antibodies, fluorophores, chemiluminescent agents, enzymes and antibodies which can serve as specific binding pair members for a labelled
30 ligand. The choice of label depends on sensitivity required, ease of conjugation with the compound, stability requirements, and available instrumentation.

5 Appropriate *in vivo* models for demonstrating efficacy in treating inflammatory responses include EAE (experimental autoimmune encephalomyelitis) in mice, rats, guinea pigs or primates, as well as other inflammatory models dependent upon $\alpha 4$ integrins.

10 Compounds having the desired biological activity may be modified as necessary to provide desired properties such as improved pharmacological properties (e.g., *in vivo* stability, bio-availability), or the ability to be detected in diagnostic applications. Stability can be assayed in a variety of ways such as by measuring the half-life of the proteins during incubation with
15 peptidases or human plasma or serum. A number of such protein stability assays have been described (see, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokinet., 1990, 15(2):83-93).

20 For diagnostic purposes, a wide variety of labels may be linked to the compounds, which may provide, directly or indirectly, a detectable signal. Thus, the compounds of the subject invention may be modified in a variety of ways for a variety of end purposes while still retaining biological activity. In addition, various reactive sites may be introduced at the terminus for linking to particles, solid substrates, macromolecules, or the like.

25 Labeled compounds can be used in a variety of *in vivo* or *in vitro* applications. A wide variety of labels may be employed, such as radionuclides (e.g., gamma-emitting radioisotopes such as technetium-99 or indium-111), fluorescers (e.g., fluorescein), enzymes, enzyme substrates,
30 enzyme cofactors, enzyme inhibitors, chemiluminescent compounds, bioluminescent compounds, and the like. Those of ordinary skill in the art will know of other suitable labels for binding to the complexes, or will be able to ascertain such using routine experimentation. The binding of these

5 labels is achieved using standard techniques common to those of ordinary skill in the art.

10 *In vitro* uses include diagnostic applications such as monitoring inflammatory responses by detecting the presence of leukocytes expressing VLA-4. The compounds of this invention can also be used for isolating or labeling such cells. In addition, as mentioned above, the compounds of the invention can be used to assay for potential inhibitors of VLA-4/VCAM-1 interactions.

15 For *in vivo* diagnostic imaging to identify, e.g., sites of inflammation, radioisotopes are typically used in accordance with well known techniques. The radioisotopes may be bound to the peptide either directly or indirectly using intermediate functional groups. For instance, chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules have been used to bind proteins to metallic ion
20 radioisotopes.

25 The complexes can also be labeled with a paramagnetic isotope for purposes of *in vivo* diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR), both of which are well known. In general, any conventional method for visualizing diagnostic imaging can be used. Usually gamma- and positron-emitting radioisotopes are used for camera imaging and paramagnetic isotopes are used for MRI. Thus, the compounds can be used to monitor the course of amelioration of an inflammatory
30 response in an individual. By measuring the increase or decrease in lymphocytes expressing VLA-4 it is possible to determine whether a particular therapeutic regimen aimed at ameliorating the disease is effective.

5 The pharmaceutical compositions of the present invention can be used to
block or inhibit cellular adhesion associated with a number of diseases and
disorders. For instance, a number of inflammatory disorders are associated
with integrins or leukocytes. Treatable disorders include, e.g.,
transplantation rejection (e.g., allograft rejection), Alzheimer's disease,
10 atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset
diabetes), retinitis, cancer metastases, rheumatoid arthritis, acute
leukocyte-mediated lung injury (e.g., adult respiratory distress syndrome),
asthma, nephritis, and acute and chronic inflammation, including atopic
dermatitis, psoriasis, myocardial ischemia, and inflammatory bowel disease
15 (including Crohn's disease and ulcerative colitis). In preferred embodiments
the pharmaceutical compositions are used to treat inflammatory brain
disorders, such as multiple sclerosis (MS), viral meningitis and encephalitis.

 Inflammatory bowel disease is a collective term for two similar diseases
20 referred to as Crohn's disease and ulcerative colitis. Crohn's disease is an
idiopathic, chronic ulceroconstrictive inflammatory disease characterized by
sharply delimited and typically transmural involvement of all layers of the
bowel wall by a granulomatous inflammatory reaction. Any segment of the
gastrointestinal tract, from the mouth to the anus, may be involved, although
25 the disease most commonly affects the terminal ileum and/or colon.
Ulcerative colitis is an inflammatory response limited largely to the colonic
mucosa and submucosa. Lymphocytes and macrophages are numerous in
lesions of inflammatory bowel disease and may contribute to inflammatory
injury.

30 Asthma is a disease characterized by increased responsiveness of the
tracheobronchial tree to various stimuli potentiating paroxysmal constriction
of the bronchial airways. The stimuli cause release of various mediators of
inflammation from IgE-coated mast cells including histamine, eosinophilic

5 and neutrophilic chemotactic factors, leukotrienes, prostaglandin and platelet activating factor. Release of these factors recruits basophils, eosinophils and neutrophils, which cause inflammatory injury.

10 Atherosclerosis is a disease of arteries (e.g., coronary, carotid, aorta and iliac). The basic lesion, the atheroma, consists of a raised focal plaque within the intima, having a core of lipid and a covering fibrous cap. Atheromas compromise arterial blood flow and weaken affected arteries. Myocardial and cerebral infarcts are a major consequence of this disease. Macrophages and leukocytes are recruited to atheromas and contribute to inflammatory injury.

15 Rheumatoid arthritis is a chronic, relapsing inflammatory disease that primarily causes impairment and destruction of joints. Rheumatoid arthritis usually first affects the small joints of the hands and feet but then may involve the wrists, elbows, ankles and knees. The arthritis results from interaction of synovial cells with leukocytes that infiltrate from the circulation into the synovial lining of the joints. See *e.g.*, Paul, *Immunology* (3d ed., Raven Press, 1993).

25 Another indication for the compounds of this invention is in treatment of organ or graft rejection mediated by VLA-4. Over recent years there has been a considerable improvement in the efficiency of surgical techniques for transplanting tissues and organs such as skin, kidney, liver, heart, lung, pancreas and bone marrow. Perhaps the principal outstanding problem is the lack of satisfactory agents for inducing immunotolerance in the recipient to the transplanted allograft or organ. When allogeneic cells or organs are transplanted into a host (i.e., the donor and donee are different individuals from the same species), the host immune system is likely to mount an immune response to foreign antigens in the transplant (host-versus-graft disease)

30

5 leading to destruction of the transplanted tissue. CD8⁺ cells, CD4 cells and
monocytes are all involved in the rejection of transplant tissues. Compounds
of this invention which bind to alpha-4 integrin are useful, *inter alia*, to block
alloantigen-induced immune responses in the donee thereby preventing such
cells from participating in the destruction of the transplanted tissue or organ.
10 See, *e.g.*, Paul et al., *Transplant International* 9, 420-425 (1996);
Georczynski et al., *Immunology* 87, 573-580 (1996); Georczynski et al.,
Transplant. Immunol. 3, 55-61 (1995); Yang et al., *Transplantation* 60, 71-
76 (1995); Anderson et al., *APMIS* 102, 23-27 (1994).

15 A related use for compounds of this invention which bind to VLA-4 is in
modulating the immune response involved in "graft versus host" disease
(GVHD). See *e.g.*, Schlegel et al., *J. Immunol.* 155, 3856-3865 (1995).
GVHD is a potentially fatal disease that occurs when immunologically
competent cells are transferred to an allogeneic recipient. In this situation,
20 the donor's immunocompetent cells may attack tissues in the recipient.
Tissues of the skin, gut epithelia and liver are frequent targets and may be
destroyed during the course of GVHD. The disease presents an especially
severe problem when immune tissue is being transplanted, such as in bone
marrow transplantation; but less severe GVHD has also been reported in
25 other cases as well, including heart and liver transplants. The therapeutic
agents of the present invention are used, *inter alia*, to block activation of the
donor T-cells thereby interfering with their ability to lyse target cells in the
host.

30 A further use of the compounds of this invention is inhibiting tumor
metastasis. Several tumor cells have been reported to express VLA-4 and
compounds which bind VLA-4 block adhesion of such cells to endothelial
cells. Steinback et al., *Urol. Res.* 23, 175-83 (1995); Orosz et al., *Int. J.*

5 *Cancer* 60, 867-71 (1995); Freedman et al., *Leuk. Lymphoma* 13, 47-52
(1994); Okahara et al., *Cancer Res.* 54, 3233-6 (1994).

10 A further use of the compounds of this invention is in treating multiple
sclerosis. Multiple sclerosis is a progressive neurological autoimmune
disease that affects an estimated 250,000 to 350,000 people in the United
States. Multiple sclerosis is thought to be the result of a specific autoimmune
reaction in which certain leukocytes attack and initiate the destruction of
myelin, the insulating sheath covering nerve fibers. In an animal model for
multiple sclerosis, murine monoclonal antibodies directed against VLA-4
15 have been shown to block the adhesion of leukocytes to the endothelium, and
thus prevent inflammation of the central nervous system and subsequent
paralysis in the animals¹⁶.

20 Pharmaceutical compositions of the invention are suitable for use in a
variety of drug delivery systems. Suitable formulations for use in the present
invention are found in *Remington's Pharmaceutical Sciences*, Mace
Publishing Company, Philadelphia, PA, 17th ed. (1985).

25 In order to enhance serum half-life, the compounds may be encapsulated,
introduced into the lumen of liposomes, prepared as a colloid, or other
conventional techniques may be employed which provide an extended serum
half-life of the compounds. A variety of methods are available for preparing
liposomes, as described in, e.g., Szoka, et al., U.S. Patent Nos. 4,235,871,
4,501,728 and 4,837,028 each of which is incorporated herein by reference.

30 The amount administered to the patient will vary depending upon what is
being administered, the purpose of the administration, such as prophylaxis or
therapy, the state of the patient, the manner of administration, and the like.
In therapeutic applications, compositions are administered to a patient already

09910702-072001

5 suffering from a disease in an amount sufficient to cure or at least partially
arrest the symptoms of the disease and its complications. An amount
adequate to accomplish this is defined as "therapeutically effective dose."
Amounts effective for this use will depend on the disease condition being
treated as well as by the judgment of the attending clinician depending upon
10 factors such as the severity of the inflammation, the age, weight and general
condition of the patient, and the like.

09910702 1072001
15 The compositions administered to a patient are in the form of
pharmaceutical compositions described above. These compositions may be
sterilized by conventional sterilization techniques, or may be sterile filtered.
The resulting aqueous solutions may be packaged for use as is, or lyophilized,
the lyophilized preparation being combined with a sterile aqueous carrier
prior to administration. The pH of the compound preparations typically will
be between 3 and 11, more preferably from 5 to 9 and most preferably from 7
20 to 8. It will be understood that use of certain of the foregoing excipients,
carriers, or stabilizers will result in the formation of pharmaceutical salts.

25 The therapeutic dosage of the compounds of the present invention will
vary according to, for example, the particular use for which the treatment is
made, the manner of administration of the compound, the health and
condition of the patient, and the judgment of the prescribing physician. For
example, for intravenous administration, the dose will typically be in the
range of about 20 μg to about 500 μg per kilogram body weight, preferably
about 100 μg to about 300 μg per kilogram body weight. Suitable dosage
30 ranges for intranasal administration are generally about 0.1 pg to 1 mg per
kilogram body weight. Effective doses can be extrapolated from
dose-response curves derived from *in vitro* or animal model test systems.

5 Compounds of this invention are also capable of binding or antagonizing
the actions of $\alpha_6\beta_1$, $\alpha_9\beta_1$, $\alpha_4\beta_7$, $\alpha_d\beta_2$, $\alpha_c\beta_7$ integrins (although $\alpha_4\beta_1$ and $\alpha_9\beta_1$
are preferred in this invention). Accordingly, compounds of this invention
are also useful for preventing or reversing the symptoms, disorders or
diseases induced by the binding of these integrins to their respective ligands.

10 For example, International Publication Number WO 98/53817, published
December 3, 1998 (the disclosure of which is incorporated herein by
reference in its entirety) and references cited therein describe disorders
mediated by $\alpha_4\beta_7$. This reference also describes an assay for determining
15 antagonism of $\alpha_4\beta_7$ dependent binding to VCAM-Ig fusion protein.

20 Additionally, compounds that bind $\alpha_d\beta_2$ and $\alpha_c\beta_7$ integrins are
particularly useful for the treatment of asthma and related lung diseases. See,
for example, M. H. Grayson et al., *J. Exp. Med.* **1998**, 188(11) 2187-2191.
Compounds that bind $\alpha_c\beta_7$ integrin are also useful for the treatment of
systemic lupus erythematosus (see, for example, M. Pang et al., *Arthritis*
Rheum. **1998**, 41(8), 1456-1463); Crohn's disease, ulcerative colitis and
inflammatory bowel disease (IBD) (see, for example, D. Elewaut et al., *Scand*
J. Gastroenterol **1998**, 33(7) 743-748); Sjogren's syndrome (see, for
25 example, U. Kroneld et al., *Scand J. Gastroenterol* **1998**, 27(3), 215-218);
and rheumatoid arthritis (see, for example, *Scand J. Gastroenterol* **1996**,
44(3), 293-298). And compounds that bind $\alpha_6\beta_1$ may be useful in preventing
fertilization (see, for example, H. Chen et al., *Chem. Biol.* **1999**, 6, 1-10).

30 Certain of the compounds within the generic formulas described herein
are also useful as synthetic intermediates for other compounds of this
invention as illustrated in the examples herein.

The following synthetic and biological examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention. Unless otherwise stated, all temperatures are in degrees Celsius.

EXAMPLES

In the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.

aq or aq.	=	aqueous
AcOH	=	acetic acid
bd	=	broad doublet
bm	=	broad multiplet
bs	=	broad singlet
Bn	=	benzyl
Boc	=	<i>N</i> - <i>tert</i> -butoxycarbonyl
Boc ₂ O	=	di- <i>tert</i> -butyl dicarbonate
BOP	=	benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate
Cbz	=	carbobenzyloxy
CHCl ₃	=	chloroform
CH ₂ Cl ₂	=	dichloromethane
(COCl) ₂	=	oxalyl chloride
d	=	doublet
dd	=	doublet of doublets
dt	=	doublet of triplets
DBU	=	1,8-diazabicyclo[5.4.0]undec-7-ene
DCC	=	1,3-dicyclohexylcarbodiimide
DMAP	=	4- <i>N,N</i> -dimethylaminopyridine
DME	=	ethylene glycol dimethyl ether
DMF	=	<i>N,N</i> -dimethylformamide
DMSO	=	dimethylsulfoxide
EDC	=	1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride
Et ₃ N	=	triethylamine
Et ₂ O	=	diethyl ether
EtOAc	=	ethyl acetate
EtOH	=	ethanol
eq or eq.	=	equivalent
Fmoc	=	<i>N</i> -(9-fluorenylmethoxycarbonyl)

000240" 20207660

5	FmocONSu	=	<i>N</i> -(9-fluorenylmethoxycarbonyl)-succinimide
	g	=	grams
	h	=	hour
	H ₂ O	=	water
10	HBr	=	hydrobromic acid
	HCl	=	hydrochloric acid
	HOBT	=	1-hydroxybenzotriazole hydrate
	hr	=	hour
	K ₂ CO ₃	=	potassium carbonate
15	L	=	liter
	m	=	multiplet
	MeOH	=	methanol
	mg	=	milligram
	MgSO ₄	=	magnesium sulfate
20	mL	=	milliliter
	mm	=	millimeter
	mM	=	millimolar
	mmol	=	millimol
	mp	=	melting point
25	N	=	normal
	NaCl	=	sodium chloride
	Na ₂ CO ₃	=	sodium carbonate
	NaHCO ₃	=	sodium bicarbonate
	NaOEt	=	sodium ethoxide
30	NaOH	=	sodium hydroxide
	NH ₄ Cl	=	ammonium chloride
	NMM	=	<i>N</i> -methylmorpholine
	Phe	=	L-phenylalanine
	Pro	=	L-proline
35	psi	=	pounds per square inch
	PtO ₂	=	platinum oxide
	q	=	quartet
	quint.	=	quintet
	rt	=	room temperature
40	s	=	singlet
	sat	=	saturated
	t	=	triplet
	<i>t</i> -BuOH	=	<i>tert</i> -butanol
	TFA	=	trifluoroacetic acid
45	THF	=	tetrahydrofuran
	TLC or tlc	=	thin layer chromatography
	Ts	=	tosyl
	TsCl	=	tosyl chloride
	TsOH	=	tosylate

5

10

2,4-Dihydroxy-3-iodopyridine Preparation Procedure

15

20

25

30

***N*-tert-Butoxycarbonyl-4-(1-methyl-4-methoxypyridin-2-one-3-yl)-L-phenylalanine Methyl Ester Preparation Procedure**

The procedure of Morera and Ortar (*Syn. Lett.* 1997, (7), 1403-1405) was used to convert 1-methyl-3-iodo-4-methoxypyridin-2-one into *N-tert*-

5 butoxycarbonyl-4-(1-methyl-4-methoxypyridin-2-one-3-yl)-L-phenylalanine
methyl ester.

Method D

BOC Removal Procedure

10 Anhydrous hydrochloride (HCl) gas was bubbled through a methanolic
solution of the appropriate Boc-amino acid ester at 0°C for 15 minutes and
the reaction mixture was stirred for three hours. The solution was
concentrated to a syrup and dissolved in Et₂O and reconcentrated. This
15 procedure was repeated and the resulting solid was placed under high vacuum
overnight.

Method E

Preparation of Dimethyl 2-Alkylmalonate

20 To a suspension of sodium hydride 60% dispersion in mineral oil (1.1
eq) in anhydrous THF was added slowly with stirring dimethyl malonate (1.1
eq), causing the evolution of gas. To the resulting solution was added a
bromoalkane, iodoalkane, or trifluoromethanesulfonyloxyalkane (1.0 eq), and
the mixture was heated to 50°C for 48 h, at which point TLC indicated
consumption of the bromoalkane, iodoalkane, or
25 trifluoromethanesulfonyloxyalkane. The mixture was diluted with diethyl
ether and washed with 70% saturated sodium chloride. The organic extracts
were treated with anhydrous magnesium sulfate, filtered, and evaporated to
afford a dimethyl 2-alkylmalonate of sufficient purity for immediate
conversion to a 5-alkyl-4,6-dihydroxypyrimidine.

Method F

Preparation of 5-Alkyl-4,6-dihydroxypyrimidine

30 To a diethyl 2-alkylmalonate or a dimethyl 2-alkylmalonate (1.0 eq) was
added formamidine acetate (1.0 eq) and 25% sodium methoxide in methanol

5 (3.3 eq). The resulting slurry was stirred vigorously and heated to 60°C for
4 h, and then allowed to cool. The slurry was diluted with water, and
acidified to pH = 2 by addition of HCl. The resulting precipitate was
collected by filtration, washed with water, and dried under vacuum, to afford
10 a 5-alkyl-4,6-dihydroxypyrimidine of sufficient purity for immediate
conversion to a 5-alkyl-4,6-dichloropyrimidine.

Method G

Preparation of

5-Alkyl-4,6-dichloropyrimidine or 5-Alkoxy-4-chloropyrimidine

15 To a 5-alkyl-4,6-dihydroxypyrimidine or a 5-alkoxy-4-
hydroxypyrimidine (1.0 eq) were added phosphorus oxychloride (15.0 eq)
and *N,N*-dimethylaniline (1.0 eq), and the mixture was heated to 100°C for 3
h, and then allowed to cool. The resulting solution was poured onto ice, and
the mixture was extracted with dichloromethane. The organic extracts were
20 treated with anhydrous magnesium sulfate, filtered, and evaporated to afford
a 5-alkyl-4,6-dichloropyrimidine or a 5-alkoxy-4-chloropyrimidine of
sufficient purity for immediate conversion to a 5-alkyl-4-*N*-alkylamino-6-
chloropyrimidine or a 5-alkoxy-4-*N*-alkylaminopyrimidine.

Method H

Preparation of

5-Alkyl-4-*N*-alkylamino-6-chloropyrimidine or

5-Alkoxy-4-*N*-alkylaminopyrimidine

25 To a solution of a 5-alkyl-4,6-dichloropyrimidine or a 5-alkoxy-4-
chloropyrimidine (1.0 eq) in ethanol were added an alkyl amine (1.2 eq,
30 typically L-4-(*N,N*-dimethylcarbamoyloxy)-phenylalanine *tert*-butyl ester) and
diisopropylethylamine (2.0 eq). The mixture was sealed in a pressure tube
and heated to 120°C for 48 h, at which point TLC indicated consumption of
the 5-alkyl-4,6-dichloropyrimidine or the 5-alkoxy-4-chloropyrimidine. The

5 mixture was evaporated, and the residue was partitioned between ethyl acetate
and pH = 4.5 citrate buffer. The organic extracts were washed with
saturated sodium chloride, treated with anhydrous magnesium sulfate,
filtered, and evaporated. The residue was purified by chromatography on
10 silica gel using ethyl acetate and hexanes to afford a pure 5-alkyl-4-*N*-
alkylamino-6-chloropyrimidine or 5-alkoxy-4-*N*-alkylaminopyrimidine.

Method I

Preparation of 5-Alkyl-4-*N*-alkylaminopyrimidine (Procedure I)

15 A suspension of 5-alkyl-4-*N*-alkylamino-6-chloropyrimidine (1.0 eq), and
an equal mass 10% palladium on carbon, and sodium bicarbonate (5.0 eq) in
methanol was shaken under 55 psi hydrogen gas for 16 h, at which point TLC
indicated consumption of the 5-alkyl-4-*N*-alkylamino-6-chloropyrimidine.
The mixture was filtered through Celite and evaporated to give a residue,
which was partitioned between ethyl acetate and 70% saturated sodium
20 chloride. The organic extracts were treated with anhydrous magnesium
sulfate, filtered, and evaporated. The residue was purified by
chromatography on silica gel using ethyl acetate and hexanes to afford a pure
5-alkyl-4-*N*-alkylaminopyrimidine.

Method J

Preparation of 5-Alkyl-4-*N*-alkylaminopyrimidine (Procedure II)

25 A suspension of 5-alkyl-4-*N*-alkylamino-6-chloropyrimidine (1.0 eq),
sodium acetate (10.0 eq), and zinc powder (20.0 eq) in a 9:1 mixture of acetic
acid and water was stirred vigorously at 40°C for 72 h, at which point TLC
30 indicated partial consumption of the 5-alkyl-4-*N*-alkylamino-6-
chloropyrimidine. The supernatant solution was decanted from remaining
zinc and evaporated. The residue was partitioned between ethyl acetate and
saturated sodium bicarbonate, and the organic extracts were treated with
anhydrous magnesium sulfate, filtered, and evaporated. The residue was

5 purified by chromatography on silica gel using ethyl acetate and hexanes to afford a pure 5-alkyl-4-*N*-alkylaminopyrimidine.

Method K

Ester Hydrolysis Procedure II

10 To a chilled (0°C) THF/H₂O solution (2:1, 5 - 10 mL) of the appropriate ester was added LiOH (1.1 equivalents). The temperature was maintained at 0°C and the reaction was complete in 1-3 hours. The reaction mixture was concentrated and the residue was taken up into H₂O and the pH adjusted to 2-
15 3 with aqueous HCl. The product was extracted with ethyl acetate and the combined organic phase was washed with brine, dried over MgSO₄, filtered and concentrated to yield the desired acid.

Method L

Preparation of 5-Iodo-4(3H)-pyrimidinone

20 The procedure of Sakamoto *et. al.* (Chem. Pharm. Bull. **1986**, 34(7), 2719-2724) was used to convert 4(3H)-pyrimidinone into 5-iodo-4(3H)-pyrimidinone.

Example 1

25 **Synthesis of**

***N*-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-2-pyridon-3-yl)phenylalanine**

2,4-Dihydroxypyridine was converted via sequential application of methods A, B and C to give *N*-*tert*-butoxycarbonyl-4-(1-methyl-4-methoxypyridin-2-one-3-yl)-L-phenylalanine methyl ester. This compound was converted via method
30 D to give 4-(1-methyl-4-methoxypyridin-2-one-3-yl)-L-phenylalanine methyl ester hydrochloride. 2,2,2-Trifluoroethyl triflate (prepared according to Gassman, *et al.* J. Org. Chem. 1984, 49(12), 2258-2273) was converted via sequential

5 application of methods E, F and G to give 4,6-dichloro-5-(2,2,2-trifluoroethyl)pyrimidine.

4-(1-Methyl-4-methoxypyridin-2-one-3-yl)-L-phenylalanine methyl ester hydrochloride and 4,6-dichloro-5-(2,2,2-trifluoroethyl)pyrimidine were coupled via method H, and the product transformed via sequential application of methods
10 I and K to give the title compound.

Physical data were as follows:

¹H NMR (CD₃OD): δ = 8.4 (s), 8.06 (s), 7.66 (d), 7.25 – 7.18 (m), 6.45 (d), 5.12 – 5.08 (m), 3.94 – 3.9 (m), 3.77 (m), 3.49 (s), 3.35-3.17 (m).

15 ¹³C NMR (CD₃OD): δ = 173.7, 164.7, 163.2, 160.0, 155.8, 153.4, 138.7, 135.9, 131.9, 131.2, 130.3, 128.0, 113.7, 95.7, 55.2, 55.1, 36.5, 36.2, 31.1, 30.7.

Biological Examples

Example A

In vitro Assay For Determining Binding of Candidate Compounds to VLA-4

20 An *in vitro* assay was used to assess binding of candidate compounds to
25 $\alpha_4\beta_1$ integrin. Compounds which bind in this assay can be used to assess VCAM-1 levels in biological samples by conventional assays (e.g., competitive assays). This assay is sensitive to IC₅₀ values as low as about 1nM.

30 The activity of $\alpha_4\beta_1$ integrin was measured by the interaction of soluble VCAM-1 with Jurkat cells (e.g., American Type Culture Collection Nos. TIB 152, TIB 153, and CRL 8163), a human T-cell line which expresses high levels of $\alpha_4\beta_1$ integrin. VCAM-1 interacts with the cell surface in an $\alpha_4\beta_1$ integrin-dependent fashion (Yednock, et al. J. Biol. Chem., 1995,
35 270:28740).

5 Recombinant soluble VCAM-1 was expressed as a chimeric fusion
protein containing the seven extracellular domains of VCAM-1 on the N-
terminus and the human IgG₁ heavy chain constant region on the C-terminus.
The VCAM-1 fusion protein was made and purified by the manner described
by Yednock, *supra*.

10 Jurkat cells were grown in RPMI 1640 supplemented with 10% fetal
bovine serum, penicillin, streptomycin and glutamine as described by
Yednock, *supra*.

15 Jurkat cells were incubated with 1.5 mM MnCl₂ and 5 µg/mL 15/7
antibody for 30 minutes on ice. Mn⁺² activates the receptor to enhance ligand
binding, and 15/7 is a monoclonal antibody that recognizes an
activated/ligand occupied conformation of α₄β₁ integrin and locks the
molecule into this conformation thereby stabilizing the VCAM-1/α₄β₁ integrin
20 interaction. Yednock, et al., *supra*. Antibodies similar to the 15/7 antibody
have been prepared by other investigators (Luque, et al, 1996, J. Biol. Chem.
271:11067) and may be used in this assay.

25 Cells were then incubated for 30 minutes at room temperature with
candidate compounds, in various concentrations ranging from 66 µM to 0.01
µM using a standard 5-point serial dilution. 15 µL soluble recombinant
VCAM-1 fusion protein was then added to Jurkat cells and incubated for 30
minutes on ice. (Yednock et al., *supra*).

30 Cells were then washed two times and resuspended in PE-conjugated
goat F(ab')₂ anti-mouse IgG Fc (Immunotech, Westbrook, ME) at 1:200 and
incubated on ice, in the dark, for 30 minutes. Cells were washed twice and
analyzed with a standard fluorescence activated cell sorter ("FACS") analysis
as described in Yednock, et al., *supra*.

5 Compounds having an IC_{50} of less than about $15\mu M$ possess binding
affinity to $\alpha_4\beta_1$.

10 When tested in this assay, each of the compound prepared in the above
examples has or is expected to have an IC_{50} of $15\mu M$ or less (or is expected
to be active *in vivo*).

Example B

***In vitro* Saturation Assay For Determining Binding of Candidate Compounds to $\alpha_4\beta_1$**

15 The following describes an *in vitro* assay to determine the plasma levels
needed for a compound to be active in the Experimental Autoimmune
Encephalomyelitis ("EAE") model, described in the next example, or in other
in vivo models.

20 Log-growth Jurkat cells are washed and resuspended in normal animal
plasma containing $20\mu g/ml$ of the 15/7 antibody (described in the above
example).

25 The Jurkat cells are diluted two-fold into either normal plasma samples
containing known candidate compound amounts in various concentrations
ranging from $66\mu M$ to $0.01\mu M$, using a standard 12 point serial dilution for
a standard curve, or into plasma samples obtained from the peripheral blood
of candidate compound-treated animals.

30 Cells are then incubated for 30 minutes at room temperature, washed
twice with phosphate-buffered saline ("PBS") containing 2% fetal bovine
serum and 1mM each of calcium chloride and magnesium chloride (assay
medium) to remove unbound 15/7 antibody.

35

5 The cells are then exposed to phycoerythrin-conjugated goat F(ab')₂ anti-mouse IgG Fc (Immunotech, Westbrook, ME), which has been adsorbed for any non-specific cross-reactivity by co-incubation with 5% serum from the animal species being studied, at 1:200 and incubated in the dark at 4°C for 30 minutes.

10 Cells are washed twice with assay medium and resuspended in the same. They are then analyzed with a standard fluorescence activated cell sorter ("FACS") analysis as described in Yednock et al. J. Biol. Chem., 1995, 270:28740.

15 The data is then graphed as fluorescence versus dose, e.g., in a normal dose-response fashion. The dose levels that result in the upper plateau of the curve represent the levels needed to obtain efficacy in an *in vivo* model.

20 This assay may also be used to determine the plasma levels needed to saturate the binding sites of other integrins, such as the $\alpha_9\beta_1$ integrin, which is the integrin most closely related $\alpha_4\beta_1$ (Palmer et al, 1993, J. Cell Bio., 123:1289). Such binding is predictive of *in vivo* utility for inflammatory conditions mediated by $\alpha_9\beta_1$ integrin, including by way of example, airway hyper-responsiveness and occlusion that occurs with chronic asthma, smooth muscle cell proliferation in atherosclerosis, vascular occlusion following angioplasty, fibrosis and glomerular scarring as a result of renal disease, aortic stenosis, hypertrophy of synovial membranes in rheumatoid arthritis, and inflammation and scarring that occur with the progression of ulcerative colitis and Crohn's disease.

25 Accordingly, the above-described assay may be performed with a human colon carcinoma cell line, SW 480 (ATTC #CCL228) transfected with cDNA encoding α_9 integrin (Yokosaki et al., 1994, J. Biol. Chem., 269:26691), in

5 place of the Jurkat cells, to measure the binding of the $\alpha_9\beta_1$ integrin. As a control, SW 480 cells which express other α and β_1 subunits may be used.

10 Accordingly, another aspect of this invention is directed to a method for treating a disease in a mammalian patient, which disease is mediated by $\alpha_9\beta_1$, and which method comprises administering to said patient a therapeutically effective amount of a compound of this invention. Such compounds are preferably administered in a pharmaceutical composition described herein above. Effective daily dosing will depend upon the age, weight, condition of the patient which factors can be readily ascertained by the attending clinician. However, in a preferred embodiment, the compounds are administered from about 20 to 500 $\mu\text{g/kg}$ per day.

Example C

In vivo Evaluation

20 The standard multiple sclerosis model, Experimental Autoimmune (or Allergic) Encephalomyelitis ("EAE"), was used to determine the effect of candidate compounds to reduce motor impairment in rats or guinea pigs. Reduction in motor impairment is based on blocking adhesion between leukocytes and the endothelium and correlates with anti-inflammatory activity in the candidate compound. This model has been previously described by Keszthelyi et al., Neurology, 1996, 47:1053-1059, and measures the delay of onset of disease.

30 Brains and spinal cords of adult Hartley guinea pigs were homogenized in an equal volume of phosphate-buffered saline. An equal volume of Freund's complete adjuvant (100 mg *mycobacterium tuberculosis* plus 10 ml Freund's incomplete adjuvant) was added to the homogenate. The mixture was emulsified by circulating it repeatedly through a 20 ml syringe with a peristaltic pump for about 20 minutes.

35

5

Female Lewis rats (2-3 months old, 170-220 g) or Hartley guinea pigs (20 day old, 180-200 g) were anesthetized with isoflurane and three injections of the emulsion, 0.1 ml each, were made in each flank. Motor impairment onset is seen in approximately 9 days.

10

Candidate compound treatment began on Day 8, just before onset of symptoms. Compounds were administered subcutaneously ("SC"), orally ("PO") or intraperitoneally ("IP"). Doses were given in a range of 10mg/kg to 200 mg/kg, bid, for five days, with typical dosing of 10 to 100 mg/kg SC, 10 to 50 mg/kg PO, and 10 to 100 mg/kg IP.

15

Antibody GG5/3 against $\alpha_4\beta_1$ integrin (Keszthelyi et al., Neurology, 1996, 47:1053-1059), which delays the onset of symptoms, was used as a positive control and was injected subcutaneously at 3 mg/kg on Day 8 and 11.

20

Body weight and motor impairment were measured daily. Motor impairment was rated with the following clinical score:

25

0	no change
1	tail weakness or paralysis
2	hindlimb weakness
3	hindlimb paralysis
4	moribund or dead

30

A candidate compound was considered active if it delayed the onset of symptoms, e.g., produced clinical scores no greater than 2 or slowed body weight loss as compared to the control.

35

Example D

Asthma Model

Inflammatory conditions mediated by $\alpha_4\beta_1$ integrin include, for example, airway hyper-responsiveness and occlusion that occurs with chronic asthma. The following describes an asthma model which can be used to study the *in vivo* effects of the compounds of this invention for use in treating asthma.

Following the procedures described by Abraham et al, J. Clin. Invest, 93:776-787 (1994) and Abraham et al, Am J. Respir Crit Care Med, 156:696-703 (1997), both of which are incorporated by reference in their entirety. Compounds of this invention are formulated into an aerosol and administered to sheep which are hypersensitive to *Ascaris suum* antigen. Compounds which decrease the early antigen-induced bronchial response and/or block the late-phase airway response, e.g., have a protective effect against antigen-induced late responses and airway hyper-responsiveness ("AHR"), are considered to be active in this model.

Allergic sheep which are shown to develop both early and late bronchial responses to inhaled *Ascaris suum* antigen are used to study the airway effects of the candidate compounds. Following topical anesthesia of the nasal passages with 2% lidocaine, a balloon catheter is advanced through one nostril into the lower esophagus. The animals are then intubated with a cuffed endotracheal tube through the other nostril with a flexible fiberoptic bronchoscope as a guide.

Pleural pressure is estimated according to Abraham (1994). Aerosols (see formulation below) are generated using a disposable medical nebulizer that provides an aerosol with a mass median aerodynamic diameter of $3.2 \mu\text{m}$ as determined with an Andersen cascade impactor. The nebulizer is connected to a dosimeter system consisting of a solenoid valve and a source

5 of compressed air (20 psi). The output of the nebulizer is directed into a plastic T-piece, one end of which is connected to the inspiratory port of a piston respirator. The solenoid valve is activated for 1 second at the beginning of the inspiratory cycle of the respirator. Aerosols are delivered at V_T of 500 ml and a rate of 20 breaths/minute. A 0.5% sodium bicarbonate
10 solution only is used as a control.

To assess bronchial responsiveness, cumulative concentration-response curves to carbachol can be generated according to Abraham (1994).
15 Bronchial biopsies can be taken prior to and following the initiation of treatment and 24 hours after antigen challenge. Bronchial biopsies can be preformed according to Abraham (1994).

An *in vitro* adhesion study of alveolar macrophages can also be performed according to Abraham (1994), and a percentage of adherent cells is
20 calculated.

Aerosol Formulation

A solution of the candidate compound in 0.5% sodium bicarbonate/saline (w/v) at a concentration of 30.0 mg/mL is prepared using the following
25 procedure:

A. Preparation of 0.5% Sodium Bicarbonate / Saline Stock Solution: 100.0 mL

30

Ingredient	Gram / 100.0 mL	Final Concentration
Sodium Bicarbonate	0.5 g	0.5%
Saline	q.s. ad 100.0 mL	q.s. ad 100%

Procedure:

1. Add 0.5g sodium bicarbonate into a 100 mL volumetric flask.
2. Add approximately 90.0 mL saline and sonicate until dissolved.
3. Q.S. to 100.0 mL with saline and mix thoroughly.

B. Preparation of 30.0 mg/mL Candidate Compound: 10.0 mL

Ingredient	Gram / 10.0 mL	Final Concentration
Candidate Compound	0.300 g	30.0 mg/mL
0.5% Sodium Bicarbonate / Saline Stock Solution	q.s. ad 10.0 mL	q.s ad 100%

Procedure:

1. Add 0.300 g of the candidate compound into a 10.0 mL volumetric flask.
2. Add approximately 9.7 mL of 0.5% sodium bicarbonate / saline stock solution.
3. Sonicate until the candidate compound is completely dissolved.
4. Q.S. to 10.0 mL with 0.5% sodium bicarbonate / saline stock solution and mix thoroughly.

Using a conventional oral formulation, compounds of this invention would be active in this model.

Example E
Allograft Model

Allograft rejection, associated with infiltration of inflammatory cells, is the leading obstacle to long-term allograft survival. Cell surface adhesion molecules facilitate alloantigen recognition *in vitro* and may be critical for

5 lymphocyte traffic *in vivo*. The following describes a model which can be used to study the *in vivo* effects of the compounds of this invention in the control of allograft rejection.

10 The following procedures are described in Coito et al., *Transplantation* (1998) **65(6)**:699-706 and in Korom et al., *Transplantation* (1998) **65(6)**:854-859, both of which are incorporated by reference in their entirety.

15 Following the procedures described in Coito and Korom, male adult rats weighing approximately 200 - 250 g are used in this model. Lewis rats are used as the recipients of cardiac allografts from Lewis X Brown Norway rats. Hearts are transplanted into the abdominal great vessels using standard microvascular techniques.

20 A candidate compound is administered to the transplant recipient in a suitable pharmaceutical carrier for a 7-day course of treatment starting the day of the engraftment. Doses range from 0.3 to 30 mg/kg/day. Control recipients receive the pharmaceutical carrier only. The rats are euthanized and their cardiac allografts are analyzed as described in Coito and Korom..

25 Using conventional formulations, compounds of this invention would be active in this model.

100220 20207660